DYRK1A-related intellectual disability syndrome

Mendelian MONDO:0013578 Pathograph 25 Show in embeddings browser Neurodevelopmental Disorder

DYRK1A-related intellectual disability syndrome (intellectual developmental disorder, autosomal dominant 7; MRD7; OMIM 614104) is a rare, typically de novo autosomal dominant neurodevelopmental disorder caused by heterozygous loss-of-function (haploinsufficiency) of DYRK1A, a dosage-sensitive kinase in the Down syndrome critical region at 21q22.13. It is characterized by microcephaly, global developmental delay and intellectual disability with prominent expressive-language impairment, autism spectrum disorder, feeding difficulties, febrile seizures and later epilepsy, short stature, a recognizable facial gestalt, and frequent ocular abnormalities.

Ask OpenScientist

Ask a research question about DYRK1A-related intellectual disability syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

3
Pathophys.
22
Phenotypes
2
Gaps
25
Pathograph
1
Genes
5
Medical Actions
9
References
1
Deep Research
?

Discussions and Knowledge Gaps

2
What is the true population-level prevalence and incidence of DYRK1A-related intellectual disability syndrome in the general population, as opposed to its enrichment within ASD cohorts?
KNOWLEDGE GAP OPEN disc_dyrk1a_population_prevalence
Available estimates derive from ASD-ascertained cohorts (DYRK1A disrupted in 0.1-0.5% of the ASD population) rather than population registries. The disorder is described as very rare and is likely underdiagnosed before broad exome/genome testing, so a robust population prevalence is not established.
Posed 2026-06-04T00:00:00Z
Show evidence (1 reference)
PMID:29034068 PARTIAL Human Clinical
"DYRK1A is a gene recurrently disrupted in 0.1-0.5% of the ASD population."
The available frequency estimate is anchored to the ASD population, not the general population, leaving the true population prevalence unresolved.
Can lithium or downstream-substrate-targeting strategies (e.g., enhancing residual DYRK1A function) be translated into disease-modifying therapy for human DYRK1A syndrome?
EMERGING HYPOTHESIS OPEN disc_dyrk1a_lithium_therapeutic_lead
Because the syndrome is a haploinsufficiency disorder, DYRK1A-inhibitor strategies developed for Down syndrome (gene-dosage increase) are mechanistically inappropriate. Instead, preclinical work suggests restoring DYRK1A function or compensating downstream circuitry: early lithium rescued multiple phenotypes in a patient-mutation knock-in mouse, and enhancing a DYRK1A-dependent inhibitory circuit reversed social-recognition deficits in Dyrk1a+/- mice. Neither approach has been tested clinically in MRD7.
Proposed experiments
Cross-model validation and biomarker-guided trial design for DYRK1A restorative therapy
exp_dyrk1a_lithium_translation
Test whether early lithium or DYRK1A-substrate-targeting interventions improve neurodevelopmental outcomes in additional DYRK1A patient-mutation models, and assess the feasibility and safety of a biomarker-guided clinical study in MRD7.
Posed 2026-06-04T00:00:00Z
Show evidence (1 reference)
PMID:37797581 SUPPORT Model Organism
"targeting DYRK1A synaptic and circuit substrates as "enhancers of DYRK1A function" harbors the potential to reverse Dyrk1a haploinsufficiency-associated circuit and cognition impairments."
Provides a mechanistic rationale for enhancer-of-function strategies as a therapeutic direction for the haploinsufficiency disorder.
⚙

Pathophysiology

3
DYRK1A Haploinsufficiency
DYRK1A-related intellectual disability syndrome is caused by heterozygous loss-of-function variants (truncating mutations, deletions, and disruptive missense changes) in DYRK1A, typically arising de novo. DYRK1A encodes a dosage-sensitive dual-specificity tyrosine-phosphorylation-regulated kinase that maps to the Down syndrome critical region on chromosome 21q22.13. Whereas copy-number gain (trisomy 21) increases DYRK1A dosage, loss-of-function variants produce haploinsufficiency, establishing DYRK1A as a dosage-sensitive gene in which both increased and decreased dosage impair neurodevelopment.
Neuron CL:0000540
Protein Phosphorylation GO:0006468 ↓ DECREASED
Downstream
Disrupted Cortical Neurogenesis and Cell-Cycle Control Reduced DYRK1A kinase dosage disrupts cell-cycle control of cortical neural stem cells, impairing neuron production.
Impaired Neocortical Circuit Development and E/I Imbalance Reduced DYRK1A dosage alters the balance of excitatory and inhibitory neocortical neurons and synapses, producing circuit-level dysfunction.
Deeply set eyes
Feeding difficulties
Constipation
Ocular abnormalities
Refractive error
Strabismus
Optic nerve hypoplasia
Cardiac anomalies
Foot anomalies
Show evidence (3 references)
PMID:25707398 SUPPORT Human Clinical
"Truncation of DYRK1A in patients with developmental delay (DD) and autism spectrum disorder (ASD) suggests a different pathology associated with loss-of-function mutations."
Establishes that DYRK1A loss-of-function (haploinsufficiency) underlies the syndrome, distinct from the gene-dosage increase seen in trisomy 21.
PMID:26677511 SUPPORT Human Clinical
"DYRK1A syndrome is an autosomal dominant disorder typically caused by a de novo pathogenic variant."
GeneReviews confirms the autosomal dominant, typically de novo origin of pathogenic DYRK1A variants causing haploinsufficiency.
PMID:25944381 SUPPORT Human Clinical
"Dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1 A (DYRK1A ) is a highly conserved gene located in the Down syndrome critical region. It has an important role in early development and regulation of neuronal proliferation."
The foundational syndrome-delineation cohort establishes DYRK1A as a Down syndrome critical region gene with a role in early development and neuronal proliferation, underlying its dosage sensitivity.
Disrupted Cortical Neurogenesis and Cell-Cycle Control
DYRK1A regulates the cell cycle of cortical neural stem cells (radial glia) by controlling nuclear Cyclin D1 levels and G1-phase length, thereby balancing proliferative versus neurogenic divisions. Altered DYRK1A dosage disrupts the coupling of cell-cycle regulation and neuron production, producing a deficit in cortical projection neurons that underlies microcephaly and impaired corticogenesis. This dosage-sensitive control of neurogenesis explains how both DYRK1A loss-of-function (syndrome) and gain (Down syndrome) converge on cortical neuronal deficits.
Neural Stem Cell (Radial Glia) CL:0000047 Cortical Projection Neuron CL:0000540
Neurogenesis GO:0022008 ↓ DECREASED Cerebral Cortex Development GO:0021987 ⚠ ABNORMAL Cell Cycle G1 Phase Regulation GO:0007049 ⚠ ABNORMAL Neural Precursor Cell Proliferation GO:0061351 ↓ DECREASED
Downstream
Intellectual disability
Global developmental delay
Microcephaly
Impaired speech development
Short stature
Intrauterine growth retardation
Show evidence (4 references)
PMID:26137553 SUPPORT Model Organism
"the human DYRK1A kinase on chromosome 21 tightly regulates the nuclear levels of Cyclin D1 in embryonic cortical stem (radial glia) cells"
Demonstrates the molecular role of DYRK1A in cell-cycle control of cortical neural stem cells via Cyclin D1, the dosage-sensitive node linking DYRK1A to corticogenesis.
PMID:26137553 SUPPORT Model Organism
"These alterations promote asymmetric proliferative divisions at the expense of neurogenic divisions, producing a deficit in cortical projection neurons that persists in postnatal stages."
Shows that DYRK1A dosage perturbation shifts the balance away from neurogenic divisions, producing a cortical neuron deficit underlying microcephaly.
PMID:40182141 SUPPORT In Vitro
"the overall impact is a marked reduction in hNSC proliferation."
In human neural stem cells, DYRK1A knockdown produces a marked reduction in proliferation, providing human-cell evidence that reduced DYRK1A dosage impairs neural precursor proliferation and corticogenesis (microcephaly).
+ 1 more reference
Impaired Neocortical Circuit Development and E/I Imbalance
Beyond its early role in neural precursor proliferation, DYRK1A regulates the assembly of neocortical and hippocampal circuits. Reduced DYRK1A dosage alters the proportions of excitatory and inhibitory neurons and synapses, producing an excitatory/inhibitory (E/I) imbalance. At the circuit level, DYRK1A controls a hippocampal mossy fiber to parvalbumin interneuron feed-forward inhibition pathway required for social recognition. This circuit-level dysfunction provides a mechanistic link between DYRK1A haploinsufficiency and the autistic behavior, social-cognition deficits, and seizure susceptibility of the syndrome, acting downstream of and in parallel to the early neurogenic defect.
Cortical Projection Neuron CL:0000540 Parvalbumin-Positive Inhibitory Interneuron CL:0000099
Cerebral Cortex Development GO:0021987 ⚠ ABNORMAL Synaptic Signaling GO:0099536 ⚠ ABNORMAL
Downstream
Autistic behavior
Seizures
Febrile seizures
Hypertonia
Gait disturbance
Motor stereotypy
Anxiety
Show evidence (3 references)
PMID:30831192 SUPPORT Model Organism
"haploinsufficient Dyrk1a+/- mutant mice mirror the neurological traits associated with the human pathology, such as defective social interactions, stereotypic behaviors and epileptic activity."
Dyrk1a+/- mice recapitulate the core neurological traits of the human syndrome, validating haploinsufficiency as the disease mechanism.
PMID:30831192 SUPPORT Model Organism
"These mutant mice present altered proportions of excitatory and inhibitory neocortical neurons and synapses."
Demonstrates that DYRK1A haploinsufficiency shifts the balance of excitatory and inhibitory neocortical neurons and synapses, establishing E/I imbalance as a circuit-level mechanism.
PMID:37797581 SUPPORT Model Organism
"we identify a social experience-sensitive mechanism in hippocampal mossy fiber-parvalbumin interneuron (PV IN) synapses by which DYRK1A recruits feedforward inhibition of CA3 and CA2 to promote social recognition."
Maps a specific DYRK1A-dependent inhibitory circuit (mossy fiber to PV interneuron feed-forward inhibition) controlling social recognition, linking DYRK1A dosage to the social-cognition/autistic phenotype.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for DYRK1A-related intellectual disability syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

22
Cardiovascular 1
Cardiac anomalies Abnormal heart morphology HP:0001627
Show evidence (2 references)
PMID:26677511 SUPPORT Human Clinical
"Ophthalmologic, urogenital, cardiac, and/or dental anomalies have been reported."
GeneReviews lists cardiac anomalies among the reported organ-system manifestations of DYRK1A syndrome.
PMID:33562844 SUPPORT Human Clinical
"cardiac features (including ventricular septal defect, patent ductus arteriosus, aortic valve disease)"
Specific cardiac defects reported in DYRK1A syndrome include ventricular septal defect, patent ductus arteriosus, and aortic valve disease.
Digestive 2
Feeding difficulties FREQUENT Feeding difficulties HP:0011968
Show evidence (1 reference)
PMID:37740550 SUPPORT Human Clinical
"Low birth weight, growth restriction with feeding difficulties, stature insufficiency, and microcephaly are frequently reported."
Feeding difficulties are frequently reported and contribute to growth restriction in DYRK1A syndrome.
Constipation Constipation HP:0002019
Show evidence (1 reference)
PMID:26677511 SUPPORT Human Clinical
"standard treatment for orthopedic, dental, cardiac, urogenital, ophthalmologic, constipation, and other medical issues."
GeneReviews explicitly lists constipation among the medical issues requiring standard treatment in DYRK1A syndrome.
Eye 2
Deeply set eyes Deeply set eye HP:0000490
Show evidence (1 reference)
PMID:33562844 SUPPORT Human Clinical
"It has a particular facial gestalt of deep-set eyes, short nose with a broad tip, up-slanting palpebral fissures"
Deep-set eyes are explicitly named as a defining feature of the DYRK1A syndrome facial gestalt.
Strabismus Strabismus HP:0000486
Show evidence (1 reference)
PMID:33562844 SUPPORT Human Clinical
"strabismus (21.1%, 19/90)"
Strabismus was present in 21.1% (19/90) of individuals with ocular features.
Head and Neck 1
Microcephaly VERY_FREQUENT Microcephaly HP:0000252
Show evidence (2 references)
PMID:25707398 SUPPORT Human Clinical
"It was characterized by ID, ASD, microcephaly, intrauterine growth retardation, febrile seizures in infancy, impaired speech, stereotypic behavior, hypertonia and a specific facial gestalt."
Microcephaly is a core component of the DYRK1A syndromic phenotype in the defining cohort.
PMID:25944381 SUPPORT Human Clinical
"All individuals shared congenital microcephaly at birth"
All individuals in the foundational cohort had congenital microcephaly, supporting a VERY_FREQUENT classification.
Musculoskeletal 1
Hypertonia Hypertonia HP:0001276
Show evidence (1 reference)
PMID:26677511 SUPPORT Human Clinical
"a typical facial gestalt, feeding problems, seizures, hypertonia, gait disturbances, and foot anomalies."
GeneReviews lists hypertonia among the clinically recognizable features.
Nervous System 8
Intellectual disability VERY_FREQUENT Intellectual disability HP:0001249
Show evidence (2 references)
PMID:26677511 SUPPORT Human Clinical
"DYRK1A syndrome is characterized by intellectual disability including impaired speech development"
GeneReviews lists intellectual disability as a defining feature of the syndrome.
PMID:37497568 SUPPORT Human Clinical
"Diagnosis of ASD was confirmed in 85% and ID was confirmed in 89% of participants with DYRK1A syndrome."
In a dedicated cohort of 29 individuals with DYRK1A LGD variants, intellectual disability was confirmed in 89%, supporting a VERY_FREQUENT classification.
Global developmental delay VERY_FREQUENT Global developmental delay HP:0001263
Show evidence (2 references)
PMID:37740550 SUPPORT Human Clinical
"Haploinsufficiency of DYRK1A causes a syndrome with global psychomotor delay and intellectual disability."
Global psychomotor delay is described as a defining consequence of DYRK1A haploinsufficiency.
PMID:25944381 SUPPORT Human Clinical
"All individuals shared congenital microcephaly at birth, intellectual disability, developmental delay, severe speech impairment, short stature, and distinct facial features."
Developmental delay was present in all individuals in the foundational syndrome-delineation cohort.
Autistic behavior VERY_FREQUENT Autistic behavior HP:0000729
Show evidence (2 references)
PMID:26677511 SUPPORT Human Clinical
"autism spectrum disorder including anxious and/or stereotypic behavior problems"
GeneReviews documents ASD with stereotypic/anxious behavior as a characteristic feature.
PMID:37497568 SUPPORT Human Clinical
"Diagnosis of ASD was confirmed in 85% and ID was confirmed in 89% of participants with DYRK1A syndrome."
ASD was confirmed in 85% of a 29-individual DYRK1A LGD cohort, supporting a VERY_FREQUENT classification.
Seizures FREQUENT Seizure HP:0001250
Show evidence (1 reference)
PMID:26677511 SUPPORT Human Clinical
"the development of epilepsy with seizures of the atonic, absence, and generalized myoclonic types"
GeneReviews documents epilepsy with multiple generalized seizure types in DYRK1A syndrome.
Febrile seizures Febrile seizure (within the age range of 3 months to 6 years) HP:0002373
Temporal: RECURRENT
Show evidence (1 reference)
PMID:38179410 SUPPORT Human Clinical
"Intellectual disability-7 (MRD7) is a subtype disorder of intellectual disability (MRD) involving feeding difficulties, hypoactivity, and febrile seizures at an age of early onset"
Febrile seizures of early onset are described as a defining feature of MRD7 (DYRK1A syndrome).
Impaired speech development VERY_FREQUENT Delayed speech and language development HP:0000750
Show evidence (1 reference)
PMID:26677511 SUPPORT Human Clinical
"DYRK1A syndrome is characterized by intellectual disability including impaired speech development"
GeneReviews documents impaired speech development as part of the core neurodevelopmental phenotype.
Gait disturbance Gait disturbance HP:0001288
Show evidence (1 reference)
PMID:26677511 SUPPORT Human Clinical
"a typical facial gestalt, feeding problems, seizures, hypertonia, gait disturbances, and foot anomalies."
GeneReviews lists gait disturbances among the recognizable clinical features.
Anxiety Anxiety HP:0000739
Show evidence (2 references)
PMID:26677511 SUPPORT Human Clinical
"autism spectrum disorder including anxious and/or stereotypic behavior problems"
GeneReviews lists anxious behavior problems as part of the autism-spectrum behavioral phenotype of DYRK1A syndrome.
PMID:33562844 SUPPORT Human Clinical
"febrile seizures, anxiety, altered stress reactions"
Anxiety and altered stress reactions are reported among the recurrent findings in DYRK1A-related intellectual disability syndrome.
Growth 2
Short stature FREQUENT Short stature HP:0004322
Show evidence (1 reference)
PMID:26677511 SUPPORT Human Clinical
"Other medical concerns relate to febrile seizures in infancy; the development of epilepsy with seizures of the atonic, absence, and generalized myoclonic types; short stature; and gastrointestinal problems."
GeneReviews lists short stature among the recurrent medical concerns in DYRK1A syndrome.
Intrauterine growth retardation Intrauterine growth retardation HP:0001511
Show evidence (1 reference)
PMID:25707398 SUPPORT Human Clinical
"It was characterized by ID, ASD, microcephaly, intrauterine growth retardation, febrile seizures in infancy, impaired speech, stereotypic behavior, hypertonia and a specific facial gestalt."
Intrauterine growth retardation is part of the defining DYRK1A syndromic phenotype.
Other 5
Ocular abnormalities FREQUENT Abnormality of the eye HP:0000478
Show evidence (1 reference)
PMID:33562844 SUPPORT Human Clinical
"Ninety out of 145 patients (62.1%) with heterozygous DYRK1A variants"
In a pooled cohort/literature analysis of 145 individuals, 62.1% had ocular features, establishing ocular abnormalities as a frequent comorbidity.
Refractive error Abnormality of refraction HP:0000539
Show evidence (1 reference)
PMID:33562844 SUPPORT Human Clinical
"refractive error (35.6%, 32/90)"
Refractive error was the most common ocular pathology, seen in 35.6% (32/90) of individuals with ocular features.
Optic nerve hypoplasia Optic nerve hypoplasia HP:0000609
Show evidence (1 reference)
PMID:33562844 SUPPORT Human Clinical
"optic nerve hypoplasia (13%, 12/90)"
Optic nerve hypoplasia was present in 13% (12/90) of individuals with ocular features and is a significant cause of visual impairment.
Motor stereotypy Motor stereotypy HP:0000733
Show evidence (1 reference)
PMID:25707398 SUPPORT Human Clinical
"It was characterized by ID, ASD, microcephaly, intrauterine growth retardation, febrile seizures in infancy, impaired speech, stereotypic behavior, hypertonia and a specific facial gestalt."
Stereotypic behavior is part of the defining DYRK1A syndromic phenotype.
Foot anomalies Abnormal foot morphology HP:0001760
Show evidence (2 references)
PMID:26677511 SUPPORT Human Clinical
"typical facial gestalt, feeding problems, seizures, hypertonia, gait disturbances, and foot anomalies."
GeneReviews lists foot anomalies among the clinically recognizable features of DYRK1A syndrome.
PMID:33562844 SUPPORT Human Clinical
"Hand and foot abnormalities include long tapered fingers, small hands and feet, toe syndactyly and high arched feet"
Foot abnormalities in DYRK1A syndrome include small feet, toe syndactyly, and high arched feet.
🧬

Genetic Associations

1
DYRK1A (CAUSAL)
Gene: DYRK1A hgnc:3091 variant_origin: DE_NOVO
Autosomal dominant
Show evidence (4 references)
PMID:25707398 SUPPORT Human Clinical
"Comparison of our data and published cases with 8696 controls identified a significant enrichment of DYRK1A truncating mutations (P=0.00851) and an excess of de novo mutations"
Demonstrates statistically significant enrichment of de novo DYRK1A truncating mutations in affected individuals, establishing causation.
PMID:26677511 SUPPORT Human Clinical
"DYRK1A syndrome is an autosomal dominant disorder typically caused by a de novo pathogenic variant."
GeneReviews confirms autosomal dominant inheritance with typically de novo pathogenic variants.
PMID:25944381 SUPPORT Human Clinical
"We have identified 14 individuals with de novo heterozygous variants of DYRK1A; five with microdeletions, three with small insertions or deletions (INDELs) and six with deleterious SNVs."
Documents the spectrum of de novo DYRK1A variant types (microdeletions, INDELs, deleterious SNVs) underlying haploinsufficiency.
+ 1 more reference
💊

Medical Actions

5
Antiepileptic Pharmacotherapy
Action: Pharmacotherapy NCIT:C15986
Routine treatment of epilepsy under the care of a neurologist for the febrile, atonic, absence, and generalized myoclonic seizures seen in DYRK1A syndrome.
Show evidence (1 reference)
PMID:26677511 SUPPORT Human Clinical
"routine treatment of epilepsy under the care of a neurologist"
GeneReviews recommends routine neurologist-directed treatment of epilepsy.
Educational and Developmental Therapy
Action: Rehabilitation NCIT:C15315
Educational and therapy programs (e.g., speech, occupational, physical, and behavioral therapy) tailored to the individual's developmental needs.
Show evidence (1 reference)
PMID:26677511 SUPPORT Human Clinical
"Educational and therapy programs to address the specific needs identified"
GeneReviews recommends individualized educational and therapy programs as the mainstay of management.
Nutritional Support and Feeding Management
Action: Supportive Care NCIT:C15747
Monitoring of growth parameters, nutritional status, and safety of oral intake, with supportive feeding management for feeding difficulties.
Show evidence (1 reference)
PMID:26677511 SUPPORT Human Clinical
"growth parameters and nutritional status, and safety of oral intake"
GeneReviews recommends surveillance of growth, nutrition, and oral-intake safety, supporting nutritional/feeding management.
Ophthalmologic Evaluation and Surveillance
Action: eye examination MAXO:0001155
Referral to ophthalmology as part of the management care pathway, with regular detailed ophthalmologic assessment (especially in childhood) to detect and treat refractive error, strabismus, and optic nerve abnormalities and to prevent amblyopia.
Show evidence (1 reference)
PMID:33562844 SUPPORT Human Clinical
"Patients with DYRK1A variants should be referred to ophthalmology as part of their management care pathway to prevent amblyopia in children and reduce visual comorbidity"
The ocular-phenotype study explicitly recommends ophthalmology referral as part of the DYRK1A syndrome management care pathway.
Genetic Counseling
Action: Genetic Counseling NCIT:C15240
Genetic counseling for families, with the option of prenatal molecular diagnosis, given the autosomal dominant, typically de novo inheritance and the availability of trio-based exome sequencing.
Show evidence (1 reference)
PMID:38179410 SUPPORT Human Clinical
"We provided prenatal diagnosis for the three families and genetic"
Demonstrates that trio-WES-based diagnosis enables genetic counseling and prenatal molecular diagnosis for affected families.
{ }

Source YAML

click to show 
name: DYRK1A-related intellectual disability syndrome
creation_date: "2026-06-03T00:00:00Z"
category: Mendelian
disease_term:
  preferred_term: DYRK1A-related intellectual disability syndrome
  term:
    id: MONDO:0013578
    label: DYRK1A-related intellectual disability syndrome
parents:
- Neurodevelopmental Disorder
description: >
  DYRK1A-related intellectual disability syndrome (intellectual developmental
  disorder, autosomal dominant 7; MRD7; OMIM 614104) is a rare, typically de
  novo autosomal dominant neurodevelopmental disorder caused by heterozygous
  loss-of-function (haploinsufficiency) of DYRK1A, a dosage-sensitive kinase in
  the Down syndrome critical region at 21q22.13. It is characterized by
  microcephaly, global developmental delay and intellectual disability with
  prominent expressive-language impairment, autism spectrum disorder, feeding
  difficulties, febrile seizures and later epilepsy, short stature, a recognizable
  facial gestalt, and frequent ocular abnormalities.
synonyms:
- DYRK1A syndrome
- Intellectual developmental disorder, autosomal dominant 7
- MRD7
- Mental retardation, autosomal dominant 7
- DYRK1A haploinsufficiency syndrome
references:
- reference: PMID:26677511
  title: "DYRK1A Syndrome."
  tags:
  - GeneReviews
- reference: PMID:25944381
  title: "DYRK1A haploinsufficiency causes a new recognizable syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies."
- reference: PMID:33562844
  title: "Ocular Phenotype Associated with DYRK1A Variants."
- reference: PMID:37497568
  title: "Characterizing the autism spectrum phenotype in DYRK1A-related syndrome."
- reference: PMID:40182141
  title: "DYRK1A roles in human neural progenitors."
- reference: PMID:30831192
  title: "Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome."
- reference: PMID:37797581
  title: "An inhibitory circuit-based enhancer of DYRK1A function reverses Dyrk1a-associated impairment in social recognition."
- reference: PMID:39633007
  title: "Lithium normalizes ASD-related neuronal, synaptic, and behavioral phenotypes in DYRK1A-knockin mice."
- reference: PMID:38179410
  title: "Identification of two novel and one rare mutation in DYRK1A and prenatal diagnoses in three Chinese families with intellectual Disability-7."

pathophysiology:
- name: DYRK1A Haploinsufficiency
  description: >
    DYRK1A-related intellectual disability syndrome is caused by heterozygous
    loss-of-function variants (truncating mutations, deletions, and disruptive
    missense changes) in DYRK1A, typically arising de novo. DYRK1A encodes a
    dosage-sensitive dual-specificity tyrosine-phosphorylation-regulated kinase
    that maps to the Down syndrome critical region on chromosome 21q22.13.
    Whereas copy-number gain (trisomy 21) increases DYRK1A dosage,
    loss-of-function variants produce haploinsufficiency, establishing DYRK1A as
    a dosage-sensitive gene in which both increased and decreased dosage impair
    neurodevelopment.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Protein Phosphorylation
    term:
      id: GO:0006468
      label: protein phosphorylation
    modifier: DECREASED
  downstream:
  - target: Disrupted Cortical Neurogenesis and Cell-Cycle Control
    description: >-
      Reduced DYRK1A kinase dosage disrupts cell-cycle control of cortical
      neural stem cells, impairing neuron production.
  - target: Impaired Neocortical Circuit Development and E/I Imbalance
    description: >-
      Reduced DYRK1A dosage alters the balance of excitatory and inhibitory
      neocortical neurons and synapses, producing circuit-level dysfunction.
  - target: Deeply set eyes
  - target: Feeding difficulties
  - target: Constipation
  - target: Ocular abnormalities
  - target: Refractive error
  - target: Strabismus
  - target: Optic nerve hypoplasia
  - target: Cardiac anomalies
  - target: Foot anomalies
  evidence:
  - reference: PMID:25707398
    reference_title: "Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Truncation of DYRK1A in patients with developmental delay (DD) and \nautism spectrum disorder (ASD) suggests a different pathology associated with \nloss-of-function mutations."
    explanation: >
      Establishes that DYRK1A loss-of-function (haploinsufficiency) underlies the
      syndrome, distinct from the gene-dosage increase seen in trisomy 21.
  - reference: PMID:26677511
    reference_title: "DYRK1A Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "DYRK1A syndrome is an autosomal dominant disorder typically \ncaused by a de novo pathogenic variant."
    explanation: >
      GeneReviews confirms the autosomal dominant, typically de novo origin of
      pathogenic DYRK1A variants causing haploinsufficiency.
  - reference: PMID:25944381
    reference_title: "DYRK1A haploinsufficiency causes a new recognizable syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1 A (DYRK1A ) is \na highly conserved gene located in the Down syndrome critical region. It has an \nimportant role in early development and regulation of neuronal proliferation."
    explanation: >
      The foundational syndrome-delineation cohort establishes DYRK1A as a Down
      syndrome critical region gene with a role in early development and neuronal
      proliferation, underlying its dosage sensitivity.

- name: Disrupted Cortical Neurogenesis and Cell-Cycle Control
  description: >
    DYRK1A regulates the cell cycle of cortical neural stem cells (radial glia)
    by controlling nuclear Cyclin D1 levels and G1-phase length, thereby
    balancing proliferative versus neurogenic divisions. Altered DYRK1A dosage
    disrupts the coupling of cell-cycle regulation and neuron production,
    producing a deficit in cortical projection neurons that underlies
    microcephaly and impaired corticogenesis. This dosage-sensitive control of
    neurogenesis explains how both DYRK1A loss-of-function (syndrome) and gain
    (Down syndrome) converge on cortical neuronal deficits.
  cell_types:
  - preferred_term: Neural Stem Cell (Radial Glia)
    term:
      id: CL:0000047
      label: neural stem cell
  - preferred_term: Cortical Projection Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Neurogenesis
    term:
      id: GO:0022008
      label: neurogenesis
    modifier: DECREASED
  - preferred_term: Cerebral Cortex Development
    term:
      id: GO:0021987
      label: cerebral cortex development
    modifier: ABNORMAL
  - preferred_term: Cell Cycle G1 Phase Regulation
    term:
      id: GO:0007049
      label: cell cycle
    modifier: ABNORMAL
  - preferred_term: Neural Precursor Cell Proliferation
    term:
      id: GO:0061351
      label: neural precursor cell proliferation
    modifier: DECREASED
  evidence:
  - reference: PMID:26137553
    reference_title: "DYRK1A-mediated Cyclin D1 Degradation in Neural Stem Cells Contributes to the Neurogenic Cortical Defects in Down Syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "the human DYRK1A \nkinase on chromosome 21 tightly regulates the nuclear levels of Cyclin D1 in \nembryonic cortical stem (radial glia) cells"
    explanation: >
      Demonstrates the molecular role of DYRK1A in cell-cycle control of cortical
      neural stem cells via Cyclin D1, the dosage-sensitive node linking DYRK1A
      to corticogenesis.
  - reference: PMID:26137553
    reference_title: "DYRK1A-mediated Cyclin D1 Degradation in Neural Stem Cells Contributes to the Neurogenic Cortical Defects in Down Syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These alterations promote asymmetric proliferative divisions at the \nexpense of neurogenic divisions, producing a deficit in cortical projection \nneurons that persists in postnatal stages."
    explanation: >
      Shows that DYRK1A dosage perturbation shifts the balance away from
      neurogenic divisions, producing a cortical neuron deficit underlying
      microcephaly.
  - reference: PMID:40182141
    reference_title: "DYRK1A roles in human neural progenitors."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "the overall impact is a marked reduction in \nhNSC proliferation."
    explanation: >
      In human neural stem cells, DYRK1A knockdown produces a marked reduction in
      proliferation, providing human-cell evidence that reduced DYRK1A dosage
      impairs neural precursor proliferation and corticogenesis (microcephaly).
  - reference: PMID:40182141
    reference_title: "DYRK1A roles in human neural progenitors."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We identified 35 protein partners of DYRK1A involved in essential \npathways such as cell cycle regulation and DNA repair."
    explanation: >
      The DYRK1A interactome in human neural stem cells is enriched for cell-cycle
      regulation, mechanistically linking DYRK1A to the cell-cycle control of
      cortical progenitors.
  downstream:
  - target: Intellectual disability
  - target: Global developmental delay
  - target: Microcephaly
  - target: Impaired speech development
  - target: Short stature
  - target: Intrauterine growth retardation

- name: Impaired Neocortical Circuit Development and E/I Imbalance
  description: >
    Beyond its early role in neural precursor proliferation, DYRK1A regulates the
    assembly of neocortical and hippocampal circuits. Reduced DYRK1A dosage alters
    the proportions of excitatory and inhibitory neurons and synapses, producing an
    excitatory/inhibitory (E/I) imbalance. At the circuit level, DYRK1A controls a
    hippocampal mossy fiber to parvalbumin interneuron feed-forward inhibition
    pathway required for social recognition. This circuit-level dysfunction provides
    a mechanistic link between DYRK1A haploinsufficiency and the autistic behavior,
    social-cognition deficits, and seizure susceptibility of the syndrome, acting
    downstream of and in parallel to the early neurogenic defect.
  cell_types:
  - preferred_term: Cortical Projection Neuron
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: Parvalbumin-Positive Inhibitory Interneuron
    term:
      id: CL:0000099
      label: interneuron
  biological_processes:
  - preferred_term: Cerebral Cortex Development
    term:
      id: GO:0021987
      label: cerebral cortex development
    modifier: ABNORMAL
  - preferred_term: Synaptic Signaling
    term:
      id: GO:0099536
      label: synaptic signaling
    modifier: ABNORMAL
  evidence:
  - reference: PMID:30831192
    reference_title: "Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "haploinsufficient Dyrk1a+/- mutant mice mirror the neurological traits \nassociated with the human pathology, such as defective social interactions, \nstereotypic behaviors and epileptic activity."
    explanation: >
      Dyrk1a+/- mice recapitulate the core neurological traits of the human
      syndrome, validating haploinsufficiency as the disease mechanism.
  - reference: PMID:30831192
    reference_title: "Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These mutant mice present altered \nproportions of excitatory and inhibitory neocortical neurons and synapses."
    explanation: >
      Demonstrates that DYRK1A haploinsufficiency shifts the balance of excitatory
      and inhibitory neocortical neurons and synapses, establishing E/I imbalance
      as a circuit-level mechanism.
  - reference: PMID:37797581
    reference_title: "An inhibitory circuit-based enhancer of DYRK1A function reverses Dyrk1a-associated impairment in social recognition."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "we identify a social \nexperience-sensitive mechanism in hippocampal mossy fiber-parvalbumin \ninterneuron (PV IN) synapses by which DYRK1A recruits feedforward inhibition of \nCA3 and CA2 to promote social recognition."
    explanation: >
      Maps a specific DYRK1A-dependent inhibitory circuit (mossy fiber to PV
      interneuron feed-forward inhibition) controlling social recognition, linking
      DYRK1A dosage to the social-cognition/autistic phenotype.
  downstream:
  - target: Autistic behavior
  - target: Seizures
  - target: Febrile seizures
  - target: Hypertonia
  - target: Gait disturbance
  - target: Motor stereotypy
  - target: Anxiety

phenotypes:
- category: Phenotype
  name: Intellectual disability
  description: >
    The majority of affected individuals function in the moderate-to-severe range
    of intellectual disability; milder presentations are also reported.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:26677511
    reference_title: "DYRK1A Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "DYRK1A syndrome is characterized by intellectual \ndisability including impaired speech development"
    explanation: >
      GeneReviews lists intellectual disability as a defining feature of the
      syndrome.
  - reference: PMID:37497568
    reference_title: "Characterizing the autism spectrum phenotype in DYRK1A-related syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Diagnosis of ASD was confirmed in 85% and ID was confirmed in 89% of \nparticipants with DYRK1A syndrome."
    explanation: >
      In a dedicated cohort of 29 individuals with DYRK1A LGD variants,
      intellectual disability was confirmed in 89%, supporting a VERY_FREQUENT
      classification.

- category: Phenotype
  name: Global developmental delay
  description: >
    Global psychomotor developmental delay is detected in infancy/early childhood
    and is a near-universal early feature of DYRK1A syndrome.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:37740550
    reference_title: "Growth charts in DYRK1A syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Haploinsufficiency of DYRK1A causes a syndrome with \nglobal psychomotor delay and intellectual disability."
    explanation: >
      Global psychomotor delay is described as a defining consequence of DYRK1A
      haploinsufficiency.
  - reference: PMID:25944381
    reference_title: "DYRK1A haploinsufficiency causes a new recognizable syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All \nindividuals shared congenital microcephaly at birth, intellectual disability, \ndevelopmental delay, severe speech impairment, short stature, and distinct \nfacial features."
    explanation: >
      Developmental delay was present in all individuals in the foundational
      syndrome-delineation cohort.

- category: Phenotype
  name: Microcephaly
  description: >
    Reduced head circumference (often primary/congenital) is a hallmark and
    consistent feature of DYRK1A syndrome.
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:25707398
    reference_title: "Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It was characterized by ID, ASD, microcephaly, \nintrauterine growth retardation, febrile seizures in infancy, impaired speech, \nstereotypic behavior, hypertonia and a specific facial gestalt."
    explanation: >
      Microcephaly is a core component of the DYRK1A syndromic phenotype in the
      defining cohort.
  - reference: PMID:25944381
    reference_title: "DYRK1A haploinsufficiency causes a new recognizable syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All \nindividuals shared congenital microcephaly at birth"
    explanation: >
      All individuals in the foundational cohort had congenital microcephaly,
      supporting a VERY_FREQUENT classification.

- category: Phenotype
  name: Autistic behavior
  description: >
    Autism spectrum disorder, frequently with anxious and/or stereotypic behavior
    problems, is a characteristic feature.
  phenotype_term:
    preferred_term: Autistic behavior
    term:
      id: HP:0000729
      label: Autistic behavior
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:26677511
    reference_title: "DYRK1A Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "autism spectrum disorder \nincluding anxious and/or stereotypic behavior problems"
    explanation: >
      GeneReviews documents ASD with stereotypic/anxious behavior as a
      characteristic feature.
  - reference: PMID:37497568
    reference_title: "Characterizing the autism spectrum phenotype in DYRK1A-related syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Diagnosis of ASD was confirmed in 85% and ID was confirmed in 89% of \nparticipants with DYRK1A syndrome."
    explanation: >
      ASD was confirmed in 85% of a 29-individual DYRK1A LGD cohort, supporting a
      VERY_FREQUENT classification.

- category: Phenotype
  name: Seizures
  description: >
    Affected individuals develop febrile seizures in infancy and epilepsy with
    atonic, absence, and generalized myoclonic seizure types.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  frequency: FREQUENT
  evidence:
  - reference: PMID:26677511
    reference_title: "DYRK1A Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the development of epilepsy with \nseizures of the atonic, absence, and generalized myoclonic types"
    explanation: >
      GeneReviews documents epilepsy with multiple generalized seizure types in
      DYRK1A syndrome.

- category: Phenotype
  name: Febrile seizures
  description: >
    Febrile seizures of early onset in infancy are characteristic of DYRK1A
    syndrome and may precede the later development of afebrile epilepsy.
  phenotype_term:
    preferred_term: Febrile seizures
    term:
      id: HP:0002373
      label: Febrile seizure (within the age range of 3 months to 6 years)
    temporality: RECURRENT
  evidence:
  - reference: PMID:38179410
    reference_title: "Identification of two novel and one rare mutation in DYRK1A and prenatal diagnoses in three Chinese families with intellectual Disability-7."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Intellectual disability-7 (MRD7) is a subtype disorder \nof intellectual disability (MRD) involving feeding difficulties, hypoactivity, \nand febrile seizures at an age of early onset"
    explanation: >
      Febrile seizures of early onset are described as a defining feature of MRD7
      (DYRK1A syndrome).

- category: Phenotype
  name: Feeding difficulties
  description: >
    Feeding problems are commonly reported, contributing to growth restriction
    and requiring monitoring of nutritional status and safety of oral intake.
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  frequency: FREQUENT
  evidence:
  - reference: PMID:37740550
    reference_title: "Growth charts in DYRK1A syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Low birth weight, growth \nrestriction with feeding difficulties, stature insufficiency, and microcephaly \nare frequently reported."
    explanation: >
      Feeding difficulties are frequently reported and contribute to growth
      restriction in DYRK1A syndrome.

- category: Phenotype
  name: Impaired speech development
  description: >
    Severely impaired or absent speech development accompanies the intellectual
    disability in DYRK1A syndrome.
  phenotype_term:
    preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:26677511
    reference_title: "DYRK1A Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "DYRK1A syndrome is characterized by intellectual \ndisability including impaired speech development"
    explanation: >
      GeneReviews documents impaired speech development as part of the core
      neurodevelopmental phenotype.

- category: Phenotype
  name: Short stature
  description: >
    Postnatal growth restriction with short stature/stature insufficiency is
    frequently observed, prompting the development of syndrome-specific growth
    charts.
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  frequency: FREQUENT
  evidence:
  - reference: PMID:26677511
    reference_title: "DYRK1A Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other medical \nconcerns relate to febrile seizures in infancy; the development of epilepsy with \nseizures of the atonic, absence, and generalized myoclonic types; short stature; \nand gastrointestinal problems."
    explanation: >
      GeneReviews lists short stature among the recurrent medical concerns in
      DYRK1A syndrome.

- category: Phenotype
  name: Deeply set eyes
  description: >
    Deep-set eyes are part of the recognizable facial gestalt of DYRK1A syndrome.
  phenotype_term:
    preferred_term: Deeply set eyes
    term:
      id: HP:0000490
      label: Deeply set eye
  evidence:
  - reference: PMID:33562844
    reference_title: "Ocular Phenotype Associated with DYRK1A Variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It has a particular facial gestalt of deep-set eyes, short nose with a broad tip, up-slanting palpebral fissures"
    explanation: >
      Deep-set eyes are explicitly named as a defining feature of the DYRK1A
      syndrome facial gestalt.

- category: Phenotype
  name: Hypertonia
  description: >
    Hypertonia is part of the neurological phenotype, alongside gait disturbances.
  phenotype_term:
    preferred_term: Hypertonia
    term:
      id: HP:0001276
      label: Hypertonia
  evidence:
  - reference: PMID:26677511
    reference_title: "DYRK1A Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a typical facial gestalt, feeding problems, seizures, hypertonia, gait \ndisturbances, and foot anomalies."
    explanation: >
      GeneReviews lists hypertonia among the clinically recognizable features.

- category: Phenotype
  name: Gait disturbance
  description: >
    Gait disturbances are commonly observed and contribute to the motor phenotype.
  phenotype_term:
    preferred_term: Gait disturbance
    term:
      id: HP:0001288
      label: Gait disturbance
  evidence:
  - reference: PMID:26677511
    reference_title: "DYRK1A Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a typical facial gestalt, feeding problems, seizures, hypertonia, gait \ndisturbances, and foot anomalies."
    explanation: >
      GeneReviews lists gait disturbances among the recognizable clinical
      features.

- category: Phenotype
  name: Intrauterine growth retardation
  description: >
    Prenatal-onset growth restriction (intrauterine growth retardation, low birth
    weight) is frequently reported.
  phenotype_term:
    preferred_term: Intrauterine growth retardation
    term:
      id: HP:0001511
      label: Intrauterine growth retardation
  evidence:
  - reference: PMID:25707398
    reference_title: "Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It was characterized by ID, ASD, microcephaly, \nintrauterine growth retardation, febrile seizures in infancy, impaired speech, \nstereotypic behavior, hypertonia and a specific facial gestalt."
    explanation: >
      Intrauterine growth retardation is part of the defining DYRK1A syndromic
      phenotype.

- category: Phenotype
  name: Constipation
  description: >
    Gastrointestinal problems, including constipation, are reported and require
    standard management.
  phenotype_term:
    preferred_term: Constipation
    term:
      id: HP:0002019
      label: Constipation
  evidence:
  - reference: PMID:26677511
    reference_title: "DYRK1A Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "standard treatment for orthopedic, dental, cardiac, \nurogenital, ophthalmologic, constipation, and other medical issues."
    explanation: >
      GeneReviews explicitly lists constipation among the medical issues
      requiring standard treatment in DYRK1A syndrome.

- category: Phenotype
  name: Ocular abnormalities
  description: >
    Ocular abnormalities are a frequent and clinically actionable comorbidity in
    DYRK1A syndrome; in a combined cohort of 145 individuals, 62.1% had ocular
    manifestations, prompting recommendations for routine ophthalmology referral.
  phenotype_term:
    preferred_term: Abnormality of the eye
    term:
      id: HP:0000478
      label: Abnormality of the eye
  frequency: FREQUENT
  evidence:
  - reference: PMID:33562844
    reference_title: "Ocular Phenotype Associated with DYRK1A Variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Ninety out of 145 patients (62.1%) with heterozygous DYRK1A variants"
    explanation: >
      In a pooled cohort/literature analysis of 145 individuals, 62.1% had ocular
      features, establishing ocular abnormalities as a frequent comorbidity.

- category: Phenotype
  name: Refractive error
  description: >
    Refractive error (hyperopia/hypermetropia, myopia, astigmatism) is the most
    common ocular finding, present in 35.6% of DYRK1A individuals with ocular
    features; it is a treatable cause of visual impairment.
  phenotype_term:
    preferred_term: Refractive error
    term:
      id: HP:0000539
      label: Abnormality of refraction
  evidence:
  - reference: PMID:33562844
    reference_title: "Ocular Phenotype Associated with DYRK1A Variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "refractive error (35.6%, 32/90)"
    explanation: >
      Refractive error was the most common ocular pathology, seen in 35.6%
      (32/90) of individuals with ocular features.

- category: Phenotype
  name: Strabismus
  description: >
    Strabismus is a common ocular finding in DYRK1A syndrome, seen in 21.1% of
    individuals with ocular features, at an incidence well above the general
    population.
  phenotype_term:
    preferred_term: Strabismus
    term:
      id: HP:0000486
      label: Strabismus
  evidence:
  - reference: PMID:33562844
    reference_title: "Ocular Phenotype Associated with DYRK1A Variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "strabismus (21.1%, 19/90)"
    explanation: >
      Strabismus was present in 21.1% (19/90) of individuals with ocular features.

- category: Phenotype
  name: Optic nerve hypoplasia
  description: >
    Optic nerve hypoplasia is an important cause of visual impairment in DYRK1A
    syndrome; DYRK1A has an established role in optic nerve development, and
    Dyrk1a+/- mice show retinal ganglion cell and optic nerve axon deficits.
  phenotype_term:
    preferred_term: Optic nerve hypoplasia
    term:
      id: HP:0000609
      label: Optic nerve hypoplasia
  evidence:
  - reference: PMID:33562844
    reference_title: "Ocular Phenotype Associated with DYRK1A Variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "optic nerve hypoplasia (13%, 12/90)"
    explanation: >
      Optic nerve hypoplasia was present in 13% (12/90) of individuals with
      ocular features and is a significant cause of visual impairment.

- category: Phenotype
  name: Motor stereotypy
  description: >
    Stereotypic behaviors are very common in DYRK1A syndrome and form part of the
    behavioral/autistic phenotype.
  phenotype_term:
    preferred_term: Motor stereotypy
    term:
      id: HP:0000733
      label: Motor stereotypy
  evidence:
  - reference: PMID:25707398
    reference_title: "Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It was characterized by ID, ASD, microcephaly, \nintrauterine growth retardation, febrile seizures in infancy, impaired speech, \nstereotypic behavior, hypertonia and a specific facial gestalt."
    explanation: >
      Stereotypic behavior is part of the defining DYRK1A syndromic phenotype.

- category: Phenotype
  name: Anxiety
  description: >
    Anxiety and anxious behavior are common in DYRK1A syndrome, forming part of
    the behavioral/autistic phenotype alongside altered stress reactions.
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  evidence:
  - reference: PMID:26677511
    reference_title: "DYRK1A Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "autism spectrum disorder \nincluding anxious and/or stereotypic behavior problems"
    explanation: >
      GeneReviews lists anxious behavior problems as part of the
      autism-spectrum behavioral phenotype of DYRK1A syndrome.
  - reference: PMID:33562844
    reference_title: "Ocular Phenotype Associated with DYRK1A Variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "febrile seizures, anxiety, altered stress reactions"
    explanation: >
      Anxiety and altered stress reactions are reported among the recurrent
      findings in DYRK1A-related intellectual disability syndrome.

- category: Phenotype
  name: Cardiac anomalies
  description: >
    Congenital cardiac anomalies, including ventricular septal defect, patent
    ductus arteriosus, and aortic valve disease, are reported and warrant
    cardiac evaluation and follow-up.
  phenotype_term:
    preferred_term: Cardiac anomalies
    term:
      id: HP:0001627
      label: Abnormal heart morphology
  evidence:
  - reference: PMID:26677511
    reference_title: "DYRK1A Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Ophthalmologic, urogenital, cardiac, and/or \ndental anomalies have been reported."
    explanation: >
      GeneReviews lists cardiac anomalies among the reported organ-system
      manifestations of DYRK1A syndrome.
  - reference: PMID:33562844
    reference_title: "Ocular Phenotype Associated with DYRK1A Variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cardiac features (including ventricular septal defect, patent ductus arteriosus, aortic valve disease)"
    explanation: >
      Specific cardiac defects reported in DYRK1A syndrome include ventricular
      septal defect, patent ductus arteriosus, and aortic valve disease.

- category: Phenotype
  name: Foot anomalies
  description: >
    Foot abnormalities, including small feet, toe syndactyly, and high arched
    feet, are part of the recognizable phenotype of DYRK1A syndrome.
  phenotype_term:
    preferred_term: Foot anomalies
    term:
      id: HP:0001760
      label: Abnormal foot morphology
  evidence:
  - reference: PMID:26677511
    reference_title: "DYRK1A Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "typical facial gestalt, feeding problems, seizures, hypertonia, gait \ndisturbances, and foot anomalies."
    explanation: >
      GeneReviews lists foot anomalies among the clinically recognizable
      features of DYRK1A syndrome.
  - reference: PMID:33562844
    reference_title: "Ocular Phenotype Associated with DYRK1A Variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hand and foot abnormalities include long tapered fingers, small hands and feet, toe syndactyly and high arched feet"
    explanation: >
      Foot abnormalities in DYRK1A syndrome include small feet, toe syndactyly,
      and high arched feet.

genetic:
- name: DYRK1A
  association: CAUSAL
  variant_origin: DE_NOVO
  gene_term:
    preferred_term: DYRK1A
    term:
      id: hgnc:3091
      label: DYRK1A
  inheritance:
  - name: Autosomal dominant
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
    evidence:
    - reference: PMID:26677511
      reference_title: "DYRK1A Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "DYRK1A syndrome is an autosomal dominant disorder typically \ncaused by a de novo pathogenic variant."
      explanation: >
        GeneReviews documents autosomal dominant inheritance of DYRK1A syndrome,
        with most cases arising de novo.
  notes: >
    Dual-specificity tyrosine-phosphorylation-regulated kinase 1A. DYRK1A
    syndrome is caused by heterozygous loss-of-function variants (truncating
    variants, intragenic and larger deletions, and disruptive missense),
    typically de novo. DYRK1A is located at 21q22.13 within the Down syndrome
    critical region.
  evidence:
  - reference: PMID:25707398
    reference_title: "Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Comparison of our data and published \ncases with 8696 controls identified a significant enrichment of DYRK1A \ntruncating mutations (P=0.00851) and an excess of de novo mutations"
    explanation: >
      Demonstrates statistically significant enrichment of de novo DYRK1A
      truncating mutations in affected individuals, establishing causation.
  - reference: PMID:26677511
    reference_title: "DYRK1A Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "DYRK1A syndrome is an autosomal dominant disorder typically \ncaused by a de novo pathogenic variant."
    explanation: >
      GeneReviews confirms autosomal dominant inheritance with typically de novo
      pathogenic variants.
  - reference: PMID:25944381
    reference_title: "DYRK1A haploinsufficiency causes a new recognizable syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We have identified 14 \nindividuals with de novo heterozygous variants of DYRK1A; five with \nmicrodeletions, three with small insertions or deletions (INDELs) and six with \ndeleterious SNVs."
    explanation: >
      Documents the spectrum of de novo DYRK1A variant types (microdeletions,
      INDELs, deleterious SNVs) underlying haploinsufficiency.
  - reference: PMID:33562844
    reference_title: "Ocular Phenotype Associated with DYRK1A Variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most prevalent mutations were loss-of-function nonsense (40/108) and frameshift (39/108)."
    explanation: >
      A 108-variant landscape confirms that loss-of-function nonsense and
      frameshift variants predominate, consistent with a haploinsufficiency
      mechanism.

treatments:
- name: Antiepileptic Pharmacotherapy
  description: >
    Routine treatment of epilepsy under the care of a neurologist for the febrile,
    atonic, absence, and generalized myoclonic seizures seen in DYRK1A syndrome.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:26677511
    reference_title: "DYRK1A Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "routine treatment of epilepsy under the \ncare of a neurologist"
    explanation: >
      GeneReviews recommends routine neurologist-directed treatment of epilepsy.

- name: Educational and Developmental Therapy
  description: >
    Educational and therapy programs (e.g., speech, occupational, physical, and
    behavioral therapy) tailored to the individual's developmental needs.
  treatment_term:
    preferred_term: Rehabilitation
    term:
      id: NCIT:C15315
      label: Rehabilitation
  evidence:
  - reference: PMID:26677511
    reference_title: "DYRK1A Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Educational and therapy programs to \naddress the specific needs identified"
    explanation: >
      GeneReviews recommends individualized educational and therapy programs as
      the mainstay of management.

- name: Nutritional Support and Feeding Management
  description: >
    Monitoring of growth parameters, nutritional status, and safety of oral
    intake, with supportive feeding management for feeding difficulties.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:26677511
    reference_title: "DYRK1A Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "growth parameters and nutritional status, and safety of oral intake"
    explanation: >
      GeneReviews recommends surveillance of growth, nutrition, and oral-intake
      safety, supporting nutritional/feeding management.

- name: Ophthalmologic Evaluation and Surveillance
  description: >
    Referral to ophthalmology as part of the management care pathway, with regular
    detailed ophthalmologic assessment (especially in childhood) to detect and
    treat refractive error, strabismus, and optic nerve abnormalities and to
    prevent amblyopia.
  treatment_term:
    preferred_term: eye examination
    term:
      id: MAXO:0001155
      label: eye examination
  evidence:
  - reference: PMID:33562844
    reference_title: "Ocular Phenotype Associated with DYRK1A Variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with \nDYRK1A variants should be referred to ophthalmology as part of their management \ncare pathway to prevent amblyopia in children and reduce visual comorbidity"
    explanation: >
      The ocular-phenotype study explicitly recommends ophthalmology referral as
      part of the DYRK1A syndrome management care pathway.

- name: Genetic Counseling
  description: >
    Genetic counseling for families, with the option of prenatal molecular
    diagnosis, given the autosomal dominant, typically de novo inheritance and the
    availability of trio-based exome sequencing.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:38179410
    reference_title: "Identification of two novel and one rare mutation in DYRK1A and prenatal diagnoses in three Chinese families with intellectual Disability-7."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We provided prenatal diagnosis for the three families and genetic"
    explanation: >
      Demonstrates that trio-WES-based diagnosis enables genetic counseling and
      prenatal molecular diagnosis for affected families.

animal_models:
- species: Mouse
  genotype: Dyrk1a+/- (haploinsufficient)
  description: >
    Haploinsufficient Dyrk1a+/- mice recapitulate the core neurological traits of
    the human syndrome, including defective social interactions, stereotypic
    behaviors, and epileptic activity, and show altered proportions of excitatory
    and inhibitory neocortical neurons and synapses (E/I imbalance), validating
    haploinsufficiency as the disease mechanism.
  evidence:
  - reference: PMID:30831192
    reference_title: "Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "haploinsufficient Dyrk1a+/- mutant mice mirror the neurological traits \nassociated with the human pathology, such as defective social interactions, \nstereotypic behaviors and epileptic activity."
    explanation: >
      Dyrk1a+/- mice mirror the human neurological phenotype, confirming the
      haploinsufficiency mechanism.
- species: Mouse
  genotype: Dyrk1a-I48K knock-in (human patient mutation Ile48LysfsX2)
  description: >
    A knock-in mouse carrying the human ASD patient mutation Dyrk1a-I48K displays
    severe microcephaly, social and cognitive deficits, dendritic shrinkage,
    excitatory synaptic deficits, and altered phospho-proteomic patterns. Early
    chronic lithium treatment rescued brain volume, behavior, dendritic, synaptic,
    and signaling phenotypes into adulthood, providing a translational therapeutic
    platform.
  evidence:
  - reference: PMID:39633007
    reference_title: "Lithium normalizes ASD-related neuronal, synaptic, and behavioral phenotypes in DYRK1A-knockin mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These \nmice display severe microcephaly, social and cognitive \ndeficits, dendritic shrinkage, excitatory synaptic deficits, and altered \nphospho-proteomic patterns enriched for multiple signaling pathways and synaptic \nproteins."
    explanation: >
      The Dyrk1a-I48K knock-in mouse recapitulates microcephaly and synaptic
      deficits of the human syndrome from a patient mutation.
  - reference: PMID:39633007
    reference_title: "Lithium normalizes ASD-related neuronal, synaptic, and behavioral phenotypes in DYRK1A-knockin mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Early chronic lithium treatment of newborn mutant mice rescues the \nbrain volume, behavior, dendritic, synaptic, and signaling/synapse \nphospho-proteomic phenotypes at juvenile and adult stages."
    explanation: >
      Early chronic lithium rescues multiple phenotypes in the knock-in model,
      providing preclinical proof-of-concept for a candidate therapy.

discussions:
- discussion_id: disc_dyrk1a_population_prevalence
  prompt: >-
    What is the true population-level prevalence and incidence of DYRK1A-related
    intellectual disability syndrome in the general population, as opposed to its
    enrichment within ASD cohorts?
  kind: KNOWLEDGE_GAP
  status: OPEN
  rationale: >-
    Available estimates derive from ASD-ascertained cohorts (DYRK1A disrupted in
    0.1-0.5% of the ASD population) rather than population registries. The
    disorder is described as very rare and is likely underdiagnosed before broad
    exome/genome testing, so a robust population prevalence is not established.
  evidence:
  - reference: PMID:29034068
    reference_title: "Clinical phenotype of ASD-associated DYRK1A haploinsufficiency."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "DYRK1A is a gene recurrently disrupted in 0.1-0.5% of the ASD \npopulation."
    explanation: >
      The available frequency estimate is anchored to the ASD population, not the
      general population, leaving the true population prevalence unresolved.
  posed_date: "2026-06-04T00:00:00Z"
- discussion_id: disc_dyrk1a_lithium_therapeutic_lead
  prompt: >-
    Can lithium or downstream-substrate-targeting strategies (e.g., enhancing
    residual DYRK1A function) be translated into disease-modifying therapy for
    human DYRK1A syndrome?
  kind: EMERGING_HYPOTHESIS
  status: OPEN
  rationale: >-
    Because the syndrome is a haploinsufficiency disorder, DYRK1A-inhibitor
    strategies developed for Down syndrome (gene-dosage increase) are
    mechanistically inappropriate. Instead, preclinical work suggests restoring
    DYRK1A function or compensating downstream circuitry: early lithium rescued
    multiple phenotypes in a patient-mutation knock-in mouse, and enhancing a
    DYRK1A-dependent inhibitory circuit reversed social-recognition deficits in
    Dyrk1a+/- mice. Neither approach has been tested clinically in MRD7.
  evidence:
  - reference: PMID:37797581
    reference_title: "An inhibitory circuit-based enhancer of DYRK1A function reverses Dyrk1a-associated impairment in social recognition."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "targeting DYRK1A synaptic and circuit \nsubstrates as \"enhancers of DYRK1A function\" harbors the potential to reverse \nDyrk1a haploinsufficiency-associated circuit and cognition impairments."
    explanation: >
      Provides a mechanistic rationale for enhancer-of-function strategies as a
      therapeutic direction for the haploinsufficiency disorder.
  proposed_experiments:
  - experiment_id: exp_dyrk1a_lithium_translation
    name: Cross-model validation and biomarker-guided trial design for DYRK1A restorative therapy
    description: >-
      Test whether early lithium or DYRK1A-substrate-targeting interventions
      improve neurodevelopmental outcomes in additional DYRK1A patient-mutation
      models, and assess the feasibility and safety of a biomarker-guided clinical
      study in MRD7.
  posed_date: "2026-06-04T00:00:00Z"
📚

References & Deep Research

References

9
PMID:26677511
DYRK1A Syndrome.
No top-level findings curated for this source.
PMID:25944381
DYRK1A haploinsufficiency causes a new recognizable syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies.
No top-level findings curated for this source.
PMID:33562844
Ocular Phenotype Associated with DYRK1A Variants.
No top-level findings curated for this source.
PMID:37497568
Characterizing the autism spectrum phenotype in DYRK1A-related syndrome.
No top-level findings curated for this source.
PMID:40182141
DYRK1A roles in human neural progenitors.
No top-level findings curated for this source.
PMID:30831192
Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome.
No top-level findings curated for this source.
PMID:37797581
An inhibitory circuit-based enhancer of DYRK1A function reverses Dyrk1a-associated impairment in social recognition.
No top-level findings curated for this source.
PMID:39633007
Lithium normalizes ASD-related neuronal, synaptic, and behavioral phenotypes in DYRK1A-knockin mice.
No top-level findings curated for this source.
PMID:38179410
Identification of two novel and one rare mutation in DYRK1A and prenatal diagnoses in three Chinese families with intellectual Disability-7.
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 42 citations 2026-06-04T10:14:38.655248

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: DYRK1A-related intellectual disability syndrome
  • MONDO ID: (if available)
  • Category: Mendelian

Research Objectives

Please provide a comprehensive research report on DYRK1A-related intellectual disability syndrome covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

DYRK1A-related intellectual disability syndrome (MRD7): Comprehensive disease characteristics report

Executive summary

DYRK1A-related intellectual disability syndrome—also called Intellectual developmental disorder, autosomal dominant 7 (MRD7; OMIM #614104)—is a rare, typically de novo autosomal dominant neurodevelopmental disorder caused primarily by heterozygous loss-of-function / haploinsufficiency of DYRK1A. The most consistent clinical features across cohorts are postnatal microcephaly, global developmental delay with prominent expressive language impairment, intellectual disability, autism spectrum disorder (ASD) or autistic features, feeding difficulties, and seizures/febrile seizures, with ocular abnormalities being common and management-relevant. (bon2016disruptivedenovo pages 6-7, earl2017clinicalphenotypeof pages 1-2, oliveira2024ararecause pages 1-2, kurtz‐nelson2023characterizingtheautism pages 1-3, mejecase2021ocularphenotypeassociated pages 1-2)

A major recent diagnostic development is the clinical adoption of DNA-methylation episignatures (EpiSign) to resolve uncertain or negative genomic testing, including guiding follow-up whole-genome sequencing to detect cryptic structural variants affecting DYRK1A. (alyounis2026episignatureleadsto pages 1-2)

1. Disease information

1.1 Concise overview (definition)

DYRK1A-related intellectual disability syndrome is a rare autosomal dominant syndromic neurodevelopmental disorder characterized by developmental delay/intellectual disability with speech/language impairment, microcephaly, and a recognizable pattern of additional neurologic and systemic findings (feeding issues, seizures, behavioral/psychiatric features, and variable ocular/cardiac findings). (bon2016disruptivedenovo pages 6-7, oliveira2024ararecause pages 1-2, kurtz‐nelson2023characterizingtheautism pages 1-3)

1.2 Key identifiers and synonyms (with URLs)

  • OMIM: Intellectual developmental disorder, autosomal dominant 7 (MRD7) OMIM #614104 (explicitly cited in case literature). (alyounis2026episignatureleadsto pages 1-2, huang2023identificationoftwo pages 1-2)
  • Common names used in the literature:
  • DYRK1A syndrome (huang2023identificationoftwo pages 1-2)
  • DYRK1A-related intellectual disability syndrome / DYRK1A-related intellectual disability (mejecase2021ocularphenotypeassociated pages 1-2)
  • Legacy term in clinical case reports: “mental retardation, autosomal dominant 7” (oliveira2024ararecause pages 1-2)

Note on MONDO/Orphanet/ICD/MeSH: These identifiers were not directly retrievable with the available tools in this run; OMIM and primary literature nomenclature were used.

1.3 Source type of information

The characterization is derived predominantly from aggregated disease-level resources in primary cohorts/case series and systematic reviews (e.g., combined cohorts totaling 145 individuals for ocular phenotypes), rather than EHR-only datasets. (mejecase2021ocularphenotypeassociated pages 1-2, mejecase2021ocularphenotypeassociated pages 5-7)

2. Etiology

2.1 Disease causal factors

Primary cause: pathogenic variants affecting DYRK1A resulting in haploinsufficiency / reduced gene dosage, most frequently truncating or other likely gene-disrupting variants (nonsense, frameshift, splice), and also exon-level deletions or other structural variation. (bon2016disruptivedenovo pages 6-7, kurtz‐nelson2023characterizingtheautism pages 1-3)

Abstract quote (genetic causality): “Likely gene-disrupting (LGD) variants in DYRK1A are causative of DYRK1A syndrome and associated with autism spectrum disorder (ASD) and intellectual disability (ID).” (Kurtz-Nelson et al., Autism Research, 2023-07; https://doi.org/10.1002/aur.2995) (kurtz‐nelson2023characterizingtheautism pages 1-3)

2.2 Risk factors

For this Mendelian disorder, “risk factors” primarily reflect genetic events rather than environmental exposures.

  • Genetic risk factor: a heterozygous pathogenic DYRK1A variant, most often de novo (simplex). (oliveira2024ararecause pages 1-2, huang2023identificationoftwo pages 1-2)
  • ASD cohort enrichment: DYRK1A is “recurrently disrupted in 0.1–0.5% of the ASD population” (Earl et al., Molecular Autism, 2017-10; https://doi.org/10.1186/s13229-017-0173-5). (earl2017clinicalphenotypeof pages 1-2)

2.3 Protective factors

No validated genetic or environmental protective factors specific to MRD7 were identified in the retrieved evidence.

2.4 Gene–environment interactions

No MRD7-specific gene–environment interactions were identified in the retrieved evidence.

3. Phenotypes

3.1 Core phenotypes and frequencies (human data)

A structured summary is provided in the table artifact below.

Item type Specific item Quantitative data (with denominator) Evidence type (human cohort/case series/review) Key citation details (first author, journal, year, DOI URL) Notes
Identifier Intellectual developmental disorder, autosomal dominant 7 / MRD7 / DYRK1A syndrome OMIM 614104 Human case report / review Al-Younis, Front Genet, 2026, https://doi.org/10.3389/fgene.2026.1813300 (alyounis2026episignatureleadsto pages 1-2) Also referred to as DYRK1A-related intellectual disability syndrome.
Synonym DYRK1A-related intellectual disability syndrome — Human review Meissner, Mol Genet Genomic Med, 2020, https://doi.org/10.1002/mgg3.1544 (oliveira2024ararecause pages 2-4) Rare autosomal dominant condition due to heterozygous pathogenic variants or structural rearrangements involving DYRK1A.
Synonym Mental retardation, autosomal dominant 7 — Human case report Oliveira, Cureus, 2024, https://doi.org/10.7759/cureus.51451 (oliveira2024ararecause pages 2-4, oliveira2024ararecause pages 1-2) Older nomenclature still used in case literature.
Inheritance Autosomal dominant Usually simplex/de novo heterozygous variants Human cohort / case series Ji, Eur J Hum Genet, 2015, https://doi.org/10.1038/ejhg.2015.71 (ji2015dyrk1ahaploinsufficiencycauses media 9015eeb7, ji2015dyrk1ahaploinsufficiencycauses media 4e11df52) Most reported patients are de novo; prenatal diagnosis has been reported in families undergoing targeted testing.
Mechanism DYRK1A haploinsufficiency / likely gene-disrupting loss-of-function Predominantly truncating, frameshift, nonsense, splice, exon-level deletions Human cohort / functional interpretation Bon, Mol Psychiatry, 2016, https://doi.org/10.1038/mp.2015.5; Kurtz-Nelson, Autism Res, 2023, https://doi.org/10.1002/aur.2995 (bon2016disruptivedenovo pages 6-7, kurtz‐nelson2023characterizingtheautism pages 1-3) Core disease mechanism is reduced DYRK1A dosage; many missense variants in catalytic domain are enzymatically inactive.
Mechanism Epigenomic/episignature-supported diagnosis Positive EpiSign MRD7 episignature in 1 unresolved case Human case report Al-Younis, Front Genet, 2026, https://doi.org/10.3389/fgene.2026.1813300 (alyounis2026episignatureleadsto pages 1-2) EpiSign helped reclassify a cryptic exon 5 deletion after inconclusive exome testing; useful adjunct when standard testing is nondiagnostic.
Phenotype Microcephaly 13/14 (92.9%) Human case series Ji, Eur J Hum Genet, 2015, https://doi.org/10.1038/ejhg.2015.71 (ji2015dyrk1ahaploinsufficiencycauses media 9015eeb7, ji2015dyrk1ahaploinsufficiencycauses media 4e11df52) One of the most recognizable features; often postnatal and progressive.
Phenotype Microcephaly 15/15 (100%) Human case series Bon, Mol Psychiatry, 2016, https://doi.org/10.1038/mp.2015.5 (bon2016disruptivedenovo pages 6-7) In ASD-ascertained disruptive variant cohort.
Phenotype Microcephaly >90% of cases Human review / case report Oliveira, Cureus, 2024, https://doi.org/10.7759/cureus.51451 (oliveira2024ararecause pages 1-2) Consistent with earlier syndrome delineation studies.
Phenotype Intellectual disability (ID) 12/15 moderate-severe (80%); 3/15 mild (20%) Human case series Bon, Mol Psychiatry, 2016, https://doi.org/10.1038/mp.2015.5 (bon2016disruptivedenovo pages 6-7) Typically accompanied by major speech/language impairment.
Phenotype Intellectual disability (ID) 89% confirmed ID in DYRK1A cohort (n=29) Human cohort Kurtz-Nelson, Autism Res, 2023, https://doi.org/10.1002/aur.2995 (kurtz‐nelson2023characterizingtheautism pages 1-3) LGD variant cohort focused on ASD phenotype characterization.
Phenotype Autism spectrum disorder (ASD) 88% Human case series Bon, Mol Psychiatry, 2016, https://doi.org/10.1038/mp.2015.5 (bon2016disruptivedenovo pages 6-7) ASD is common but syndrome has a distinctive behavioral profile.
Phenotype Autism spectrum disorder (ASD) 85% confirmed ASD in DYRK1A cohort (n=29) Human cohort Kurtz-Nelson, Autism Res, 2023, https://doi.org/10.1002/aur.2995 (kurtz‐nelson2023characterizingtheautism pages 1-3) Social reciprocity, nonverbal communication, and sensory-seeking features emphasized.
Phenotype Seizures / febrile seizures 9/14 (64.3%) seizures Human case series Ji, Eur J Hum Genet, 2015, https://doi.org/10.1038/ejhg.2015.71 (ji2015dyrk1ahaploinsufficiencycauses media 9015eeb7, ji2015dyrk1ahaploinsufficiencycauses media 4e11df52) Supports frequent but not universal epilepsy risk.
Phenotype Febrile seizures 77% Human case series Bon, Mol Psychiatry, 2016, https://doi.org/10.1038/mp.2015.5 (bon2016disruptivedenovo pages 6-7) Often early onset.
Phenotype Epilepsy after febrile seizures 5/15 (33.3%) Human case series Bon, Mol Psychiatry, 2016, https://doi.org/10.1038/mp.2015.5 (bon2016disruptivedenovo pages 6-7) EEG/neurology follow-up is reasonable in symptomatic patients.
Phenotype Feeding difficulties 14/14 (100%) Human case series Ji, Eur J Hum Genet, 2015, https://doi.org/10.1038/ejhg.2015.71 (ji2015dyrk1ahaploinsufficiencycauses media 9015eeb7, ji2015dyrk1ahaploinsufficiencycauses media 4e11df52) Very common in infancy; can contribute to growth issues.
Phenotype Feeding difficulties “Vast majority” Human review / case report Oliveira, Cureus, 2024, https://doi.org/10.7759/cureus.51451 (oliveira2024ararecause pages 1-2) Early feeding/swallowing support often needed.
Phenotype Ocular features, any 90/145 (62.1%) Human pooled cohort / literature review Méjécase, Genes, 2021, https://doi.org/10.3390/genes12020234 (mejecase2021ocularphenotypeassociated pages 1-2, mejecase2021ocularphenotypeassociated pages 5-7) Ophthalmology referral recommended as part of management to reduce amblyopia/visual comorbidity.
Phenotype Refractive error 32/90 (35.6%) among those with ocular findings Human pooled cohort / literature review Méjécase, Genes, 2021, https://doi.org/10.3390/genes12020234 (mejecase2021ocularphenotypeassociated pages 1-2, mejecase2021ocularphenotypeassociated pages 5-7) Includes substantial burden of treatable visual morbidity.
Phenotype Strabismus 19/90 (21.1%) among those with ocular findings Human pooled cohort / literature review Méjécase, Genes, 2021, https://doi.org/10.3390/genes12020234 (mejecase2021ocularphenotypeassociated pages 1-2, mejecase2021ocularphenotypeassociated pages 5-7) In DSIA self-report cohort, strabismus was 14/14 (100%), but likely enriched/ascertainment-biased (mejecase2021ocularphenotypeassociated pages 2-4).
Phenotype Optic nerve hypoplasia 12/90 (13.3%) among those with ocular findings Human pooled cohort / literature review Méjécase, Genes, 2021, https://doi.org/10.3390/genes12020234 (mejecase2021ocularphenotypeassociated pages 1-2, mejecase2021ocularphenotypeassociated pages 5-7) Important cause of visual impairment; supports comprehensive eye exam.
Phenotype Ophthalmologic anomalies, any 27% Human case series Bon, Mol Psychiatry, 2016, https://doi.org/10.1038/mp.2015.5 (bon2016disruptivedenovo pages 6-7) Bon et al. recommended ophthalmologic evaluation for all affected individuals.
Phenotype Cardiac anomalies 18% Human case series Bon, Mol Psychiatry, 2016, https://doi.org/10.1038/mp.2015.5 (bon2016disruptivedenovo pages 6-7) Bon et al. recommended cardiac evaluation for all affected individuals.
Phenotype Stereotypic behaviors 91% Human case series Bon, Mol Psychiatry, 2016, https://doi.org/10.1038/mp.2015.5 (bon2016disruptivedenovo pages 6-7) Behavioral/psychiatric support often indicated.
Phenotype Anxiety 56% Human case series Bon, Mol Psychiatry, 2016, https://doi.org/10.1038/mp.2015.5 (bon2016disruptivedenovo pages 6-7) Mental health symptoms may emerge with age.
Phenotype Sleep disturbance ~50% Human case series Bon, Mol Psychiatry, 2016, https://doi.org/10.1038/mp.2015.5 (bon2016disruptivedenovo pages 6-7) Sleep review can be useful in routine care.
Phenotype Core symptom cluster in ASD-ascertained cases 89% had ≥5 key symptoms Human cohort Earl, Mol Autism, 2017, https://doi.org/10.1186/s13229-017-0173-5 (earl2017clinicalphenotypeof pages 1-2) Key profile: ID, speech/motor difficulty, microcephaly, feeding difficulty, vision abnormalities.
Phenotype Contribution to ASD population 0.1–0.5% of ASD population Human cohort / review Earl, Mol Autism, 2017, https://doi.org/10.1186/s13229-017-0173-5; Oliveira, Cureus, 2024, https://doi.org/10.7759/cureus.51451 (earl2017clinicalphenotypeof pages 1-2, oliveira2024ararecause pages 1-2) Useful prevalence estimate within ASD cohorts rather than general population prevalence.
Phenotype Disease incidence / prevalence rarity <1/1,000,000 Human review / case report Oliveira, Cureus, 2024, https://doi.org/10.7759/cureus.51451 (oliveira2024ararecause pages 1-2) Very rare disorder; likely underdiagnosed before broad exome/genome testing.
Phenotype Chinese familial/prenatal diagnosis series 3 probands, 1 fetus positive by prenatal testing Human case series Huang, Front Genet, 2023, https://doi.org/10.3389/fgene.2023.1290949 (huang2023identificationoftwo pages 9-10, huang2023identificationoftwo pages 1-2) Illustrates utility of trio-WES, confirmatory testing, prenatal diagnosis, and genetic counseling.
Mechanism/Diagnosis Molecular diagnosis by exome/genome sequencing WES/WGS identified causal SNV/CNV/deletion in reported cases Human case reports / cohorts Huang, Front Genet, 2023, https://doi.org/10.3389/fgene.2023.1290949; Al-Younis, Front Genet, 2026, https://doi.org/10.3389/fgene.2026.1813300 (alyounis2026episignatureleadsto pages 1-2, huang2023identificationoftwo pages 1-2) Real-world workflow: trio-WES ± Sanger/qPCR; if negative or VUS, consider WGS and methylation episignature testing.

Table: This table consolidates key identifiers, nomenclature, inheritance/mechanism, and the most consistently reported phenotype frequencies for DYRK1A-related intellectual disability syndrome (MRD7). It highlights human cohort evidence and practical diagnostic/management notes useful for a disease knowledge base.

Key quantitative phenotype points from landmark cohorts:

  • Microcephaly
  • 13/14 (92.9%) in the foundational syndrome delineation case series (Ji et al., 2015). (ji2015dyrk1ahaploinsufficiencycauses media 9015eeb7, ji2015dyrk1ahaploinsufficiencycauses media 4e11df52)

  • 15/15 (100%) in a de novo truncating-variant cohort ascertained for syndromic ASD/ID (Bon et al., 2016). (bon2016disruptivedenovo pages 6-7)

  • Intellectual disability and language impairment

  • Moderate–severe ID 12/15 (80%) and mild ID 3/15 (20%) (Bon et al., 2016). (bon2016disruptivedenovo pages 6-7)

  • ID confirmed in 89% of a 29-person LGD DYRK1A cohort (Kurtz-Nelson et al., 2023). (kurtz‐nelson2023characterizingtheautism pages 1-3)

  • Autism spectrum disorder (ASD)

  • ASD reported in 88% (Bon et al., 2016). (bon2016disruptivedenovo pages 6-7)

  • ASD confirmed in 85% in a 29-person LGD DYRK1A cohort (Kurtz-Nelson et al., 2023). (kurtz‐nelson2023characterizingtheautism pages 1-3)

  • Seizures

  • Seizures in 9/14 (64.3%) (Ji et al., 2015). (ji2015dyrk1ahaploinsufficiencycauses media 9015eeb7, ji2015dyrk1ahaploinsufficiencycauses media 4e11df52)

  • Febrile seizures 77% and later epilepsy 5/15 (33.3%) (Bon et al., 2016). (bon2016disruptivedenovo pages 6-7)

  • Feeding difficulties

  • 14/14 (100%) in Ji et al. (2015). (ji2015dyrk1ahaploinsufficiencycauses media 9015eeb7, ji2015dyrk1ahaploinsufficiencycauses media 4e11df52)

  • Ocular features (high clinical relevance)

  • In a combined cohort/literature analysis of 145 patients, 62.1% (90/145) had ocular manifestations (Méjécase et al., Genes, 2021-02; https://doi.org/10.3390/genes12020234). (mejecase2021ocularphenotypeassociated pages 1-2, mejecase2021ocularphenotypeassociated pages 5-7)
  • Among those with ocular findings (n=90): refractive error 35.6% (32/90), strabismus 21.1% (19/90), optic nerve hypoplasia 13% (12/90). (mejecase2021ocularphenotypeassociated pages 1-2, mejecase2021ocularphenotypeassociated pages 5-7)

3.2 Phenotype characteristics (onset, progression, severity)

  • Early onset: Developmental delay is generally detected in infancy/early childhood; expressive language is often disproportionately impaired. (oliveira2024ararecause pages 1-2, bon2016disruptivedenovo pages 6-7)
  • Course: Neurodevelopmental disability is typically lifelong; seizure phenotypes may present as febrile seizures in childhood with variable evolution to epilepsy. (bon2016disruptivedenovo pages 6-7)

3.3 Quality-of-life impact

Ocular abnormalities are emphasized as actionable comorbidities because visual impairment can compound learning/behavioral challenges; referral is recommended to reduce amblyopia/visual morbidity. (mejecase2021ocularphenotypeassociated pages 1-2)

3.4 Suggested HPO terms (non-exhaustive; for knowledge base use)

  • Microcephaly — HP:0000252
  • Global developmental delay — HP:0001263
  • Intellectual disability — HP:0001249
  • Speech delay / absent speech — HP:0000750 / HP:0001344
  • Autism — HP:0000717
  • Seizures — HP:0001250; Febrile seizures — HP:0002373
  • Feeding difficulties — HP:0011968
  • Strabismus — HP:0000486; Refractive error — HP:0000540; Optic nerve hypoplasia — HP:0000609

4. Genetic / molecular information

4.1 Causal gene

  • Gene: DYRK1A (dual-specificity tyrosine phosphorylation-regulated kinase 1A), dosage-sensitive kinase; heterozygous pathogenic variants cause MRD7. (huang2023identificationoftwo pages 1-2, kurtz‐nelson2023characterizingtheautism pages 1-3)

4.2 Pathogenic variant classes and functional consequence

  • Predominant disease mechanism: loss-of-function (LoF) leading to haploinsufficiency, commonly via nonsense, frameshift, splice site and exonic deletions. (bon2016disruptivedenovo pages 6-7, huang2023identificationoftwo pages 1-2)
  • Structural variants can be missed by exome sequencing; in one case, an MRD7 episignature prompted WGS and identification of a de novo heterozygous exon 5 deletion. (alyounis2026episignatureleadsto pages 1-2)

4.3 Modifier genes / background effects

Familial genetic background may contribute to variability in quantitative features (e.g., head circumference, IQ, ASD traits) in an ASD-ascertained cohort. (earl2017clinicalphenotypeof pages 1-2)

4.4 Epigenetic information

A clinically used MRD7-associated DNA methylation episignature (EpiSign) can support diagnosis and variant interpretation in unresolved neurodevelopmental disorder cases. (alyounis2026episignatureleadsto pages 1-2)

5. Environmental information

This is a Mendelian condition; no validated non-genetic exposures causing or preventing the syndrome were identified in the retrieved evidence.

6. Mechanism / pathophysiology

6.1 Current understanding: from gene dosage to neurodevelopmental phenotype

A convergent mechanistic picture from human genetics and model systems supports a causal chain:

1) DYRK1A haploinsufficiency → 2) disrupted neural progenitor proliferation/cell-cycle control and altered developmental gene regulation → 3) reduced neuronal output and/or altered excitatory/inhibitory (E/I) circuit composition → 4) downstream synaptic and circuit dysfunction → 5) clinical outcomes including microcephaly, ID, ASD traits, and seizures. (courraud2025dyrk1arolesin pages 1-2, arranz2019impaireddevelopmentof pages 1-2, shih2023aninhibitorycircuitbased pages 1-3)

6.2 Neural progenitor and proliferation mechanisms (human-cell evidence)

In human neural stem cells, DYRK1A depletion was studied using siRNA with proteomics and transcriptomics: * A DYRK1A interactome of 35 protein partners enriched in cell cycle regulation and DNA repair was identified. (Courraud et al., Frontiers in Neuroscience, 2025-03; https://doi.org/10.3389/fnins.2025.1533253) (courraud2025dyrk1arolesin pages 1-2) * DYRK1A knockdown led to gene-expression changes and a marked reduction in hNSC proliferation, along with decreased ERK pathway activation and p21 protein changes, supporting a mechanistic link between DYRK1A dosage and neurogenesis/microcephaly risk. (courraud2025dyrk1arolesin pages 1-2)

6.3 Circuit and synaptic mechanisms (animal-model evidence)

  • Neocortical circuit development: Dyrk1a+/− mice reportedly recapitulate social and seizure-related phenotypes and show altered excitatory vs inhibitory neuron/synapse proportions, implicating circuit-level E/I imbalance. (Arranz et al., Neurobiology of Disease, 2019-07; https://doi.org/10.1016/j.nbd.2019.02.022) (arranz2019impaireddevelopmentof pages 1-2)

  • Hippocampal inhibitory circuit mechanism (2023 landmark): A synaptic/circuit mechanism for social recognition impairment in Dyrk1a+/− mice was mapped to a mossy fiber → parvalbumin interneuron feed-forward inhibition pathway; downregulating a DYRK1A synaptic substrate (ABLIM3) restored inhibition and rescued social recognition. (Shih et al., Neuron, 2023-10; https://doi.org/10.1016/j.neuron.2023.09.009) (shih2023aninhibitorycircuitbased pages 1-3)

6.4 Recent therapeutic proof-of-concept (preclinical)

  • Lithium rescue in a human-mutation knock-in model: A DYRK1A patient mutation knock-in mouse (Dyrk1a-I48K) showed microcephaly, synaptic deficits, dendritic shrinkage, and altered phospho-proteomic patterns; early chronic lithium treatment rescued brain volume, behavioral, dendritic, synaptic, and pathway-level phospho-proteomic alterations into adulthood. (Roh et al., Molecular Psychiatry, publication month listed as 2025-12; DOI: https://doi.org/10.1038/s41380-024-02865-2) (roh2025lithiumnormalizesasdrelated pages 1-2, roh2025lithiumnormalizesasdrelated pages 10-11)

Interpretation/expert-style synthesis: Across these mechanistic studies, DYRK1A emerges as a dosage-sensitive regulator integrating (i) early neurogenesis/proliferation programs and (ii) later synaptic/circuit plasticity; this dual role provides a plausible explanation for the combination of microcephaly, persistent cognitive impairment, and ASD/seizure susceptibility. (courraud2025dyrk1arolesin pages 1-2, arranz2019impaireddevelopmentof pages 1-2, shih2023aninhibitorycircuitbased pages 1-3)

6.5 Suggested ontology terms

GO biological process (examples): * regulation of cell cycle — GO:0051726 * neural progenitor cell proliferation — GO:0061351 * neuron differentiation — GO:0030182 * synaptic signaling — GO:0099536

CL cell types (examples): * neural stem cell — CL:0000047 (supported by hNSC work) (courraud2025dyrk1arolesin pages 1-2) * parvalbumin-positive interneuron — CL:0000125 (PV interneuron circuit work) (shih2023aninhibitorycircuitbased pages 1-3)

7. Anatomical structures affected

7.1 Organ/system level

  • Primary: central nervous system/brain (microcephaly, ID, ASD features, seizures). (bon2016disruptivedenovo pages 6-7, arranz2019impaireddevelopmentof pages 1-2)
  • Common comorbidity domain: eye/visual system (high frequency of ocular findings). (mejecase2021ocularphenotypeassociated pages 1-2)

7.2 Suggested UBERON terms

  • brain — UBERON:0000955
  • cerebral cortex — UBERON:0000956
  • hippocampus — UBERON:0001954 (circuit-level mechanism work) (shih2023aninhibitorycircuitbased pages 1-3)
  • eye — UBERON:0000970 (ocular phenotype review) (mejecase2021ocularphenotypeassociated pages 1-2)

8. Temporal development

8.1 Onset

Developmental delay is typically detected early in life (infancy/early childhood) with early feeding issues and emerging neurodevelopmental phenotype. (oliveira2024ararecause pages 1-2, ji2015dyrk1ahaploinsufficiencycauses media 9015eeb7)

8.2 Progression / course

  • Neurodevelopmental impairments are generally persistent.
  • Febrile seizures may occur in childhood with a subset progressing to epilepsy. (bon2016disruptivedenovo pages 6-7)

9. Inheritance and population

9.1 Inheritance pattern

Autosomal dominant, usually de novo. (huang2023identificationoftwo pages 1-2, oliveira2024ararecause pages 1-2)

9.2 Epidemiology (available statistics)

  • Extremely rare overall: one recent case report states incidence <1/1,000,000 (Oliveira et al., Cureus, 2024-01; https://doi.org/10.7759/cureus.51451). (oliveira2024ararecause pages 1-2)
  • Within ASD cohorts: DYRK1A disruption reported in 0.1–0.5% of ASD (Earl et al., 2017). (earl2017clinicalphenotypeof pages 1-2)

Evidence gap: robust population prevalence/incidence estimates from national registries were not available in retrieved evidence.

10. Diagnostics

10.1 Clinical recognition

A highly recognizable pattern in syndromic ASD/ID includes microcephaly plus multiple features (speech/motor issues, feeding difficulty, vision abnormalities). In one cohort, 89% of DYRK1A cases had a constellation of ≥5 key symptoms. (earl2017clinicalphenotypeof pages 1-2)

10.2 Genetic testing (real-world implementation)

  • WES / trio-WES: commonly used to identify likely pathogenic DYRK1A variants and establish diagnosis in case series. (oliveira2024ararecause pages 2-4, huang2023identificationoftwo pages 1-2)
  • WGS: valuable when WES is inconclusive or when structural variants are suspected; an episignature-guided workflow identified a cryptic exon-level deletion by trio WGS. (alyounis2026episignatureleadsto pages 1-2)

10.3 Epigenomic (episignature) testing (recent development)

Abstract quote (diagnostic utility): “Episignature analysis, which detects disorder specific genome-wide DNA methylation patterns, has emerged as a functional tool to resolve diagnostic uncertainty.” (Al‑Younis et al., Frontiers in Genetics, 2026-05; https://doi.org/10.3389/fgene.2026.1813300) (alyounis2026episignatureleadsto pages 1-2)

In that case, “genome-wide DNA methylation analysis via EpiSign revealed a positive result for the episignature for Intellectual Developmental Disorder, Autosomal Dominant 7 (MRD7), associated with DYRK1A haploinsufficiency,” which then guided trio WGS to identify a de novo exon 5 deletion. (alyounis2026episignatureleadsto pages 1-2)

10.4 Differential diagnosis

MRD7 overlaps clinically with other syndromic neurodevelopmental disorders (e.g., Angelman syndrome, MECP2 disorders, Mowat–Wilson) per case-based discussion. (oliveira2024ararecause pages 1-2)

11. Outcome / prognosis

Evidence gap: The retrieved evidence does not provide robust survival/life expectancy estimates. Available data support substantial, persistent neurodevelopmental disability with variable epilepsy and treatable comorbidities (vision issues, feeding). (mejecase2021ocularphenotypeassociated pages 1-2, ji2015dyrk1ahaploinsufficiencycauses media 9015eeb7)

12. Treatment

12.1 Current clinical management (real-world)

No disease-modifying therapy is established for MRD7 in the retrieved clinical literature; care is supportive and multidisciplinary: * Early intervention therapies (speech/OT/PT) and multidisciplinary follow-up are emphasized in case-based management discussions. (oliveira2024ararecause pages 2-4)

12.2 Surveillance / specialist evaluations

  • Ophthalmology referral is recommended because ocular features are frequent and may be treatable; Méjécase et al. explicitly note referral to ophthalmology to prevent amblyopia and reduce visual comorbidity. (mejecase2021ocularphenotypeassociated pages 1-2)
  • Cardiac and ophthalmologic evaluation for all affected individuals was recommended in a de novo truncating cohort, where cardiac anomalies were 18% and ophthalmologic anomalies 27%. (bon2016disruptivedenovo pages 6-7)

12.3 Experimental / emerging targeted approaches

While not yet clinical care for MRD7, preclinical work suggests potential therapeutic avenues: * Circuit-level “downstream substrate” targeting (ABLIM3) and PV interneuron modulation rescued social recognition in Dyrk1a+/− mice (2023). (shih2023aninhibitorycircuitbased pages 1-3) * Early lithium rescued multiple phenotypes in a DYRK1A patient-mutation knock-in mouse (2025). (roh2025lithiumnormalizesasdrelated pages 1-2)

12.4 DYRK1A-targeted clinical trials in humans (adjacent indication: Down syndrome)

DYRK1A is also targeted in Down syndrome (overexpression context). These trials do not enroll MRD7 patients, but they represent real-world implementation of DYRK1A pathway modulation in humans:

  • EGCG in Down syndrome (Phase 2; completed):
  • NCT01394796 (submitted 2010): Phase 2, randomized double-masked; n=31, ages 14–29; EGCG ~9 mg/kg/day for 3 months; cognitive endpoints and DYRK1A-related biomarkers (homocysteine, etc.). (NCT01394796 chunk 1)

  • NCT01699711 (TESDAD; submitted 2012): Phase 2, randomized double-masked; n=87, ages 14–29; EGCG ~9 mg/kg/day for 12 months; cognitive battery plus biomarkers and imaging. (NCT01699711 chunk 1)

  • Pediatric EGCG safety (PERSEUS; completed):

  • NCT03624556 (submitted 2018): children 6–12 years; total enrollment 76 across DS/Fragile X cohorts; safety/tolerability emphasis with planned biomarkers (Dyrk1A/homocysteine). (NCT03624556 chunk 1, NCT03624556 chunk 3)

Expert interpretation: These DS trials provide proof that DYRK1A modulation can be operationalized clinically (dosing, biomarker strategies), but MRD7 is a haploinsufficiency disorder; translating inhibitor strategies from DS to MRD7 would be mechanistically inappropriate without a distinct rationale (i.e., MRD7 would conceptually require restoring DYRK1A function or compensating downstream circuitry). (shih2023aninhibitorycircuitbased pages 1-3)

12.5 Suggested MAXO terms (examples)

  • Speech therapy — MAXO:0000133
  • Occupational therapy — MAXO:0000017
  • Physical therapy — MAXO:0000019
  • Genetic counseling — MAXO:0000077
  • Ophthalmologic evaluation — MAXO: (term suggestion; map per MAXO version in your KB)

13. Prevention

Primary prevention is not generally applicable for a de novo Mendelian disorder, but reproductive and prenatal options are relevant: * Trio-WES-based diagnosis enables genetic counseling and prenatal molecular diagnosis in families, as demonstrated in a three-family series with prenatal testing. (huang2023identificationoftwo pages 1-2)

14. Other species / natural disease

No naturally occurring veterinary syndrome directly analogous to human MRD7 was identified in the retrieved evidence.

15. Model organisms

Model systems strongly support causality and enable mechanism/therapeutic testing:

  • Mouse Dyrk1a haploinsufficiency: recapitulates social/behavioral and seizure-related phenotypes and shows cortical circuit alterations consistent with neurodevelopmental mechanism hypotheses. (arranz2019impaireddevelopmentof pages 1-2)
  • Mouse knock-in of a human patient mutation (Dyrk1a-I48K): demonstrates synaptic and phospho-proteomic pathway dysregulation and lithium-responsive phenotypes, providing a translational platform. (roh2025lithiumnormalizesasdrelated pages 1-2, roh2025lithiumnormalizesasdrelated pages 10-11)

Key evidence images

Phenotypic details per individual in the foundational 2015 syndrome delineation series are summarized in Table 1 (cropped from the original paper). (ji2015dyrk1ahaploinsufficiencycauses media 9015eeb7, ji2015dyrk1ahaploinsufficiencycauses media 4e11df52)

Major evidence gaps (to prioritize for future KB updates)

  • MONDO/Orphanet/MeSH/ICD cross-references were not obtainable with the current tool set.
  • Limited tool-accessible data on: longitudinal natural history (adult outcomes), formal management guidelines, and population-based prevalence.
  • Limited evidence in this run on: ClinVar/ClinGen variant-level aggregation (ACMG counts, variant frequencies in gnomAD), and systematic genotype–phenotype correlation beyond the cited cohorts.

References

  1. (bon2016disruptivedenovo pages 6-7): B. Bon, B. Bon, Bradley P. Coe, R. Bernier, Cherie C Green, J. Gerdts, Kali T. Witherspoon, T. Kleefstra, M. Willemsen, Raman Kumar, P. Bosco, M. Fichera, Deana D. Li, David G. Amaral, F. Cristofoli, H. Peeters, E. Haan, C. Romano, H. Mefford, I. Scheffer, J. Gécz, B. Vries, and Evan E. Eichler. Disruptive de novo mutations of dyrk1a lead to a syndromic form of autism and id. Molecular Psychiatry, 21:126-132, Feb 2016. URL: https://doi.org/10.1038/mp.2015.5, doi:10.1038/mp.2015.5. This article has 220 citations and is from a highest quality peer-reviewed journal.

  2. (earl2017clinicalphenotypeof pages 1-2): Rachel K. Earl, Tychele N. Turner, Heather C. Mefford, Caitlin M. Hudac, Jennifer Gerdts, Evan E. Eichler, and Raphael A. Bernier. Clinical phenotype of asd-associated dyrk1a haploinsufficiency. Molecular Autism, Oct 2017. URL: https://doi.org/10.1186/s13229-017-0173-5, doi:10.1186/s13229-017-0173-5. This article has 81 citations and is from a peer-reviewed journal.

  3. (oliveira2024ararecause pages 1-2): Íris Oliveira, Andreia Fernandes, Mafalda Pereira, Márcia Rodrigues, Noémia Silva, and Carla Mendonça. A rare cause of intellectual disability. Cureus, Jan 2024. URL: https://doi.org/10.7759/cureus.51451, doi:10.7759/cureus.51451. This article has 2 citations.

  4. (kurtz‐nelson2023characterizingtheautism pages 1-3): Evangeline C. Kurtz‐Nelson, Hannah M. Rea, Aiva C. Petriceks, Caitlin M. Hudac, Tianyun Wang, Rachel K. Earl, Raphael A. Bernier, Evan E. Eichler, and Emily Neuhaus. Characterizing the autism spectrum phenotype in dyrk1a‐related syndrome. Autism Research, 16:1488-1500, Jul 2023. URL: https://doi.org/10.1002/aur.2995, doi:10.1002/aur.2995. This article has 11 citations and is from a peer-reviewed journal.

  5. (mejecase2021ocularphenotypeassociated pages 1-2): Cécile Méjécase, Christopher M. Way, Nicholas Owen, and Mariya Moosajee. Ocular phenotype associated with dyrk1a variants. Genes, 12:234, Feb 2021. URL: https://doi.org/10.3390/genes12020234, doi:10.3390/genes12020234. This article has 17 citations.

  6. (alyounis2026episignatureleadsto pages 1-2): Inas Al-Younis, Laurence Basque, Nicolas Crapoulet, Sarah Dyack, Francisco del Caño-Ochoa, Santiago Ramón-Maiques, Sara B. MacKay, Jessica Rzasa, Bekim Sadikovic, Haley McConkey, and Mouna Ben Amor. Episignature leads to diagnosis and reclassification of dyrk1a variant in a child with syndromic neurodevelopmental disorder: a case report. Frontiers in Genetics, May 2026. URL: https://doi.org/10.3389/fgene.2026.1813300, doi:10.3389/fgene.2026.1813300. This article has 0 citations and is from a peer-reviewed journal.

  7. (huang2023identificationoftwo pages 1-2): Cheng Huang, Haiyan Luo, Baitao Zeng, Chuanxin Feng, Jia Chen, Huizhen Yuan, Shuhui Huang, Bicheng Yang, Yongyi Zou, and Yanqiu Liu. Identification of two novel and one rare mutation in dyrk1a and prenatal diagnoses in three chinese families with intellectual disability-7. Frontiers in Genetics, Dec 2023. URL: https://doi.org/10.3389/fgene.2023.1290949, doi:10.3389/fgene.2023.1290949. This article has 4 citations and is from a peer-reviewed journal.

  8. (mejecase2021ocularphenotypeassociated pages 5-7): Cécile Méjécase, Christopher M. Way, Nicholas Owen, and Mariya Moosajee. Ocular phenotype associated with dyrk1a variants. Genes, 12:234, Feb 2021. URL: https://doi.org/10.3390/genes12020234, doi:10.3390/genes12020234. This article has 17 citations.

  9. (oliveira2024ararecause pages 2-4): Íris Oliveira, Andreia Fernandes, Mafalda Pereira, Márcia Rodrigues, Noémia Silva, and Carla Mendonça. A rare cause of intellectual disability. Cureus, Jan 2024. URL: https://doi.org/10.7759/cureus.51451, doi:10.7759/cureus.51451. This article has 2 citations.

  10. (ji2015dyrk1ahaploinsufficiencycauses media 9015eeb7): Jianling Ji, Hane Lee, Bob Argiropoulos, Naghmeh Dorrani, John Mann, Julian A Martinez-Agosto, Natalia Gomez-Ospina, Natalie Gallant, Jonathan A Bernstein, Louanne Hudgins, Leah Slattery, Bertrand Isidor, Cédric Le Caignec, Albert David, Ewa Obersztyn, Barbara Wiśniowiecka-Kowalnik, Michelle Fox, Joshua L Deignan, Eric Vilain, Emily Hendricks, Margaret Horton Harr, Sarah E Noon, Jessi R Jackson, Alisha Wilkens, Ghayda Mirzaa, Noriko Salamon, Jeff Abramson, Elaine H Zackai, Ian Krantz, A Micheil Innes, Stanley F Nelson, Wayne W Grody, and Fabiola Quintero-Rivera. Dyrk1a haploinsufficiency causes a new recognizable syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies. European Journal of Human Genetics, 23:1473-1481, May 2015. URL: https://doi.org/10.1038/ejhg.2015.71, doi:10.1038/ejhg.2015.71. This article has 167 citations and is from a domain leading peer-reviewed journal.

  11. (ji2015dyrk1ahaploinsufficiencycauses media 4e11df52): Jianling Ji, Hane Lee, Bob Argiropoulos, Naghmeh Dorrani, John Mann, Julian A Martinez-Agosto, Natalia Gomez-Ospina, Natalie Gallant, Jonathan A Bernstein, Louanne Hudgins, Leah Slattery, Bertrand Isidor, Cédric Le Caignec, Albert David, Ewa Obersztyn, Barbara Wiśniowiecka-Kowalnik, Michelle Fox, Joshua L Deignan, Eric Vilain, Emily Hendricks, Margaret Horton Harr, Sarah E Noon, Jessi R Jackson, Alisha Wilkens, Ghayda Mirzaa, Noriko Salamon, Jeff Abramson, Elaine H Zackai, Ian Krantz, A Micheil Innes, Stanley F Nelson, Wayne W Grody, and Fabiola Quintero-Rivera. Dyrk1a haploinsufficiency causes a new recognizable syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies. European Journal of Human Genetics, 23:1473-1481, May 2015. URL: https://doi.org/10.1038/ejhg.2015.71, doi:10.1038/ejhg.2015.71. This article has 167 citations and is from a domain leading peer-reviewed journal.

  12. (mejecase2021ocularphenotypeassociated pages 2-4): Cécile Méjécase, Christopher M. Way, Nicholas Owen, and Mariya Moosajee. Ocular phenotype associated with dyrk1a variants. Genes, 12:234, Feb 2021. URL: https://doi.org/10.3390/genes12020234, doi:10.3390/genes12020234. This article has 17 citations.

  13. (huang2023identificationoftwo pages 9-10): Cheng Huang, Haiyan Luo, Baitao Zeng, Chuanxin Feng, Jia Chen, Huizhen Yuan, Shuhui Huang, Bicheng Yang, Yongyi Zou, and Yanqiu Liu. Identification of two novel and one rare mutation in dyrk1a and prenatal diagnoses in three chinese families with intellectual disability-7. Frontiers in Genetics, Dec 2023. URL: https://doi.org/10.3389/fgene.2023.1290949, doi:10.3389/fgene.2023.1290949. This article has 4 citations and is from a peer-reviewed journal.

  14. (courraud2025dyrk1arolesin pages 1-2): Jeremie Courraud, Angélique Quartier, Nathalie Drouot, Irene Zapata-Bodalo, Johan Gilet, Alexandra Benchoua, Jean-Louis Mandel, and Amélie Piton. Dyrk1a roles in human neural progenitors. Frontiers in Neuroscience, Mar 2025. URL: https://doi.org/10.3389/fnins.2025.1533253, doi:10.3389/fnins.2025.1533253. This article has 10 citations and is from a peer-reviewed journal.

  15. (arranz2019impaireddevelopmentof pages 1-2): Juan Arranz, Elisa Balducci, Krisztina Arató, Gentzane Sánchez-Elexpuru, Sònia Najas, Alberto Parras, Elena Rebollo, Isabel Pijuan, Ionas Erb, Gaetano Verde, Ignasi Sahun, Maria J. Barallobre, José J. Lucas, Marina P. Sánchez, Susana de la Luna, and Maria L. Arbonés. Impaired development of neocortical circuits contributes to the neurological alterations in dyrk1a haploinsufficiency syndrome. Jul 2019. URL: https://doi.org/10.1016/j.nbd.2019.02.022, doi:10.1016/j.nbd.2019.02.022. This article has 40 citations and is from a domain leading peer-reviewed journal.

  16. (shih2023aninhibitorycircuitbased pages 1-3): Yu-Tzu Shih, Jason Bondoc Alipio, and Amar Sahay. An inhibitory circuit-based enhancer of dyrk1a function reverses dyrk1a-associated impairment in social recognition. Neuron, 111:3084-3101.e5, Oct 2023. URL: https://doi.org/10.1016/j.neuron.2023.09.009, doi:10.1016/j.neuron.2023.09.009. This article has 22 citations and is from a highest quality peer-reviewed journal.

  17. (roh2025lithiumnormalizesasdrelated pages 1-2): Junyeop Daniel Roh, Mihyun Bae, Hyosang Kim, Yeji Yang, Yeunkeum Lee, Yisul Cho, Suho Lee, Yan Li, Esther Yang, Hyunjee Jang, Hyeonji Kim, Hyun Kim, Hyojin Kang, Jacob Ellegood, Jason P. Lerch, Yong Chul Bae, Jin Young Kim, and Eunjoon Kim. Lithium normalizes asd-related neuronal, synaptic, and behavioral phenotypes in dyrk1a-knockin mice. Molecular Psychiatry, 30:2584-2596, Dec 2025. URL: https://doi.org/10.1038/s41380-024-02865-2, doi:10.1038/s41380-024-02865-2. This article has 5 citations and is from a highest quality peer-reviewed journal.

  18. (roh2025lithiumnormalizesasdrelated pages 10-11): Junyeop Daniel Roh, Mihyun Bae, Hyosang Kim, Yeji Yang, Yeunkeum Lee, Yisul Cho, Suho Lee, Yan Li, Esther Yang, Hyunjee Jang, Hyeonji Kim, Hyun Kim, Hyojin Kang, Jacob Ellegood, Jason P. Lerch, Yong Chul Bae, Jin Young Kim, and Eunjoon Kim. Lithium normalizes asd-related neuronal, synaptic, and behavioral phenotypes in dyrk1a-knockin mice. Molecular Psychiatry, 30:2584-2596, Dec 2025. URL: https://doi.org/10.1038/s41380-024-02865-2, doi:10.1038/s41380-024-02865-2. This article has 5 citations and is from a highest quality peer-reviewed journal.

  19. (NCT01394796 chunk 1): Egcg, a dyrk1a Inhibitor as Therapeutic Tool for Reversing Cognitive Deficits in Down Syndrome Individuals.. Parc de Salut Mar. 2010. ClinicalTrials.gov Identifier: NCT01394796

  20. (NCT01699711 chunk 1): Rafael de la Torre. Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool. Parc de Salut Mar. 2012. ClinicalTrials.gov Identifier: NCT01699711

  21. (NCT03624556 chunk 1): Rafael de la Torre. Pediatric Exploratory Research Study of EGCG Use and Safety (PERSEUS). Parc de Salut Mar. 2018. ClinicalTrials.gov Identifier: NCT03624556

  22. (NCT03624556 chunk 3): Rafael de la Torre. Pediatric Exploratory Research Study of EGCG Use and Safety (PERSEUS). Parc de Salut Mar. 2018. ClinicalTrials.gov Identifier: NCT03624556

Artifacts